<!DOCTYPE html><html lang="en-GB"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><style data-href="/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css" id="gatsby-global-css">.page-header{margin:0 0 3rem}.page-header__pre-heading{font-size:1.125rem;line-height:1.5rem;display:block;margin:0}.page-header__heading{font-size:2.75rem;line-height:3.5rem;margin:0 0 .5rem}.page-header__lead{font-size:1.25rem;line-height:1.75rem;margin:0 0 .5rem}.page-header__cta{font-size:1rem;line-height:1.5rem;display:block;margin:0}@media print{.page-header__cta{display:none!important}}.breadcrumbs{font-size:1rem;line-height:1.5rem;list-style:none;margin:.5em 0 2em;max-width:100%;padding:0}@media print{.breadcrumbs{display:none!important}}.breadcrumbs__crumb{display:inline-block}.breadcrumbs__crumb:before{content:">";font-size:80%;margin:0 .25em}.breadcrumbs__crumb:first-child:before{display:none}.breadcrumbs a{color:#222;text-decoration:underline}.breadcrumbs a:hover{text-decoration:none}.breadcrumbs a:focus{color:#005ea5}.breadcrumbs a:active{color:#222}.OldIEMessage-module--container--2Z9pT{max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);margin:auto auto 1rem}.OldIEMessage-module--alert--3CB3M{background:#ffdfa4;border:1px solid #966f2f;margin:1rem auto 0;max-width:73.125rem;padding:1rem}.OldIEMessage-module--alert--3CB3M a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.OldIEMessage-module--alert--3CB3M a:visited{color:#4c2c92}.OldIEMessage-module--alert--3CB3M a:hover{color:#2e8aca}.OldIEMessage-module--alert--3CB3M a:focus{outline:.25rem solid #0092a6;color:#005ea5}.OldIEMessage-module--alert--3CB3M a:active{color:#222}.OldIEMessage-module--alert--3CB3M h2{margin-top:0}.OldIEMessage-module--alert--3CB3M h2,.OldIEMessage-module--alert--3CB3M p{max-width:600px}.OldIEMessage-module--lastP---CQws{margin-bottom:0}.CoronaMessage-module--wrapper--zRiaV{background:#ffeb3b;padding:.5rem 0}.CoronaMessage-module--wrapper--zRiaV p{margin-top:0}.CoronaMessage-module--wrapper--zRiaV a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.CoronaMessage-module--wrapper--zRiaV a:visited{color:#4c2c92}.CoronaMessage-module--wrapper--zRiaV a:hover{color:#2e8aca}.CoronaMessage-module--wrapper--zRiaV a:focus{outline:.25rem solid #0092a6;color:#005ea5}.CoronaMessage-module--wrapper--zRiaV a:active{color:#222}@media print{.CoronaMessage-module--wrapper--zRiaV{display:none}}.CoronaMessage-module--container--36Biz{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.CoronaMessage-module--container--36Biz>:last-child{margin-bottom:0}.SubNav-module--wrapper--yAXWY{background:#fff;color:#000;display:block}.SubNav-module--list--1K9bK{margin:0;padding:0}.SubNav-module--list--1K9bK li{list-style:none;margin:0}.SubNav-module--link--39i23{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222;display:block;font-weight:400;padding:.5rem 1rem .5rem 2rem;text-decoration:none}.SubNav-module--link--39i23:focus{color:#222;outline:.25rem solid #0092a6;outline-offset:-.5rem}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222}.SubNav-module--link--39i23:hover{background:#d6d6d6;color:#222;text-decoration:underline}.SubNav-module--imageLink--3xwIS{display:none}@media(min-width:56.25em){.SubNav-module--wrapper--yAXWY{border-bottom:.125rem solid #004650;bottom:0;height:3rem;left:0;position:absolute;width:100%}.SubNav-module--imageLink--3xwIS{display:inline-block}.SubNav-module--list--1K9bK{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);height:100%}.SubNav-module--list--1K9bK li{display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23{border:0;display:block;height:100%;padding:0 1rem}.SubNav-module--link--39i23[aria-current=page],.SubNav-module--link--39i23[aria-current=true]{background:transparent}.SubNav-module--link--39i23[aria-current=page]:after,.SubNav-module--link--39i23[aria-current=true]:after{display:none}.SubNav-module--link--39i23:before{content:"";display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border:0}}.SubNav-module--image--uq-a2{height:100%}.Nav-module--link--3JzDA .Nav-module--tooltip--1Uj-W{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Nav-module--link--3JzDA:focus-visible .Nav-module--tooltip--1Uj-W{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Nav-module--visuallyHidden--ORHqX{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Nav-module--wrapper--2_xng{display:none;position:relative}@media print{.Nav-module--wrapper--2_xng{display:none!important}}@media(min-width:56.25em){.Nav-module--wrapper--2_xng{display:block}}.Nav-module--wrapperExpanded--3RxQB{display:block}.Nav-module--nav--2aQpa abbr[title]{border-bottom:0;cursor:help;text-decoration:none}.Nav-module--myAccount--3lsif{border-top:1px solid #fff}@media(min-width:56.25em){.Nav-module--myAccount--3lsif{display:none}}.Nav-module--myAccountHeading--1A5_B{border:.25rem solid #004650;font-size:100%;margin:0;padding:.5rem 1rem}.Nav-module--menuWrapper--2fp8S{background:#004650;color:#fff;padding:.25rem 0}.Nav-module--menuList--264L-{list-style:none;margin:auto;padding:0}.Nav-module--menuList--264L->li{margin:0}a.Nav-module--link--3JzDA{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#fff;display:block;font-weight:400;padding:.5rem 1rem;text-decoration:none}a.Nav-module--link--3JzDA span{text-decoration:inherit}a.Nav-module--link--3JzDA:focus{color:#fff;outline:.25rem solid #fff;outline-offset:-.5rem;z-index:1}a.Nav-module--link--3JzDA:visited{color:#fff}a.Nav-module--link--3JzDA:active{background:#acadad;color:#222}a.Nav-module--link--3JzDA:hover{background:#d6d6d6;color:#222;text-decoration:underline}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{background:#fff;color:#222;font-weight:700}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-color:#0092a6;outline-offset:-.25rem}@media(min-width:56.25em){.Nav-module--wrapperWithSubLinks--3PUfX{padding-bottom:3rem}.Nav-module--menuList--264L-{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;-webkit-flex-wrap:nowrap;flex-wrap:nowrap;-webkit-justify-content:space-between;justify-content:space-between}.Nav-module--menuList--264L->li{-webkit-flex-grow:1;flex-grow:1}a.Nav-module--link--3JzDA{border-left-width:0;border-right-width:0;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;height:100%;-webkit-justify-content:center;justify-content:center;line-height:1.25;margin:0;padding:.5rem;position:relative;text-align:center}a.Nav-module--link--3JzDA:focus{outline-offset:-.25rem}a.Nav-module--link--3JzDA span{display:inline-block;vertical-align:middle;white-space:normal}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{margin:0 .25rem}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-offset:-.5rem}a.Nav-module--link--3JzDA[aria-current=page]:after,a.Nav-module--link--3JzDA[aria-current=true]:after{background:#fff;content:"";display:block;height:.25rem;left:0;position:absolute;top:100%;width:100%}a.Nav-module--link--3JzDA[aria-current=page]:hover:after,a.Nav-module--link--3JzDA[aria-current=true]:hover:after{background:#d6d6d6}}@media(min-width:56.25em)and (min-width:75em){a.Nav-module--link--3JzDA{padding:1rem}}.Autocomplete-module--ac--2PqiF .autocomplete__wrapper{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input{-webkit-appearance:none;border:1px solid #222;border-radius:0;box-sizing:border-box;margin-bottom:0;width:100%}.Autocomplete-module--ac--2PqiF .autocomplete__input{background-color:#e9e9e9!important;height:2.5rem!important;margin:0!important;max-width:100%!important;position:relative;z-index:101}.Autocomplete-module--ac--2PqiF .autocomplete__input:focus{outline:3px solid #0092a6;outline-offset:-3px;z-index:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-webkit-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-moz-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input:-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__hint{color:#bfc1c3;position:absolute}.Autocomplete-module--ac--2PqiF .autocomplete__input--default{padding:.5rem}.Autocomplete-module--ac--2PqiF .autocomplete__input--focused{outline:3px solid #0092a6;outline-offset:-3px}.Autocomplete-module--ac--2PqiF .autocomplete__input--show-all-values{padding:4px 34px 4px 4px;cursor:pointer}.Autocomplete-module--ac--2PqiF .autocomplete__dropdown-arrow-down{z-index:-1;display:inline-block;position:absolute;right:8px;width:24px;height:24px;top:10px}.Autocomplete-module--ac--2PqiF .autocomplete__menu{background-color:#fff;border:1px solid #d6d6d6;border-top:0;color:#34384b;margin:0;max-width:100%;padding:0;text-align:left;width:-webkit-calc(100vw - 2rem);width:calc(100vw - 2rem)}@media(min-width:37.5em){.Autocomplete-module--ac--2PqiF .autocomplete__menu{width:100%}}.Autocomplete-module--ac--2PqiF .autocomplete__menu--visible{display:block}.Autocomplete-module--ac--2PqiF .autocomplete__menu--hidden{display:none}.Autocomplete-module--ac--2PqiF .autocomplete__menu--overlay{box-shadow:0 .25rem 1rem .25rem rgba(0,0,0,.1);left:0;position:absolute;top:100%;z-index:100}.Autocomplete-module--ac--2PqiF .autocomplete__menu--inline{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option{border-left-width:0;border-bottom:1px solid #d6d6d6;border-right-width:0;border-top-width:1px;color:#005ea5;cursor:pointer;display:block;margin:0;position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option a{color:inherit;display:block;font-weight:400;padding:.5rem;text-decoration:none}.Autocomplete-module--ac--2PqiF .autocomplete__option mark{background:0;color:inherit;font-weight:700;padding:0}.Autocomplete-module--ac--2PqiF .autocomplete__option>*{pointer-events:none}.Autocomplete-module--ac--2PqiF .autocomplete__option:first-of-type{border-top-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option:last-of-type{border-bottom-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option--odd{background-color:#fafafa}.Autocomplete-module--ac--2PqiF .autocomplete__option--focused,.Autocomplete-module--ac--2PqiF .autocomplete__option:hover{background-color:#e9e9e9;color:#005ea5;outline:none;text-decoration:underline}.Autocomplete-module--ac--2PqiF .autocomplete__option--no-results{background-color:#fafafa;color:#646b6f;cursor:not-allowed}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input,.Autocomplete-module--ac--2PqiF .autocomplete__option{font-size:16px;line-height:1.25}.Search-module--search--2wNll{margin:0;padding-right:2.5rem;position:relative}.Search-module--label--1rrog{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute!important;width:1px}.Search-module--button--2FbnI{background:#393939;border:0;color:#fff;cursor:pointer;height:2.5rem;min-width:2.5rem;padding:0 .5rem;position:absolute;right:0;text-align:center;top:0;z-index:101}.Search-module--button--2FbnI:focus{outline:.25rem solid #0092a6}.Search-module--button--2FbnI .Search-module--icon--2JB42{font-size:150%;vertical-align:middle}.Account-module--account--1BtRh{position:relative}.Account-module--button--zZii1{background:#fff;border:1px solid #222;color:#222;cursor:pointer;display:inline-block;font-family:inherit;font-size:inherit;font-weight:400;height:2.5rem;line-height:2.5rem;padding:0 .5rem;text-decoration:none;vertical-align:middle;white-space:nowrap}.Account-module--button--zZii1:focus{outline:.25rem solid #0092a6}.Account-module--button--zZii1:visited{color:#222}.Account-module--button--zZii1:hover{border:1px solid #222}.Account-module--myAccount--3jTaq:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Account-module--myAccount--3jTaq[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Account-module--menu--3C46i{background:#fff;border:1px solid #393939;list-style:none;margin:.625rem 0 0;padding:0;position:absolute;right:0;top:100%;z-index:2}.Account-module--menu--3C46i:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i[aria-hidden=true]{display:none}.Account-module--menu--3C46i:before{border-bottom:.5rem solid #393939;border-left:.25rem solid transparent;border-right:.25rem solid transparent}.Account-module--menu--3C46i:after,.Account-module--menu--3C46i:before{bottom:100%;content:"";display:block;height:0;position:absolute;right:1rem;width:0}.Account-module--menu--3C46i:after{border-bottom:.4rem solid #fff;border-left:.2rem solid transparent;border-right:.2rem solid transparent;margin-right:1px}.Account-module--menu--3C46i li{border-top:1px solid #d6d6d6;list-style:none;margin:0}.Account-module--menu--3C46i a{color:#005ea5;display:block;padding:.5rem 1rem;text-decoration:none;white-space:nowrap}.Account-module--menu--3C46i a:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i a:hover{background:#e9e9e9;text-decoration:underline}.Header-module--header--3os44{background:#fff;border-bottom:.125rem solid #004650;box-sizing:border-box;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif}.Header-module--header--3os44 *,.Header-module--header--3os44 :after,.Header-module--header--3os44 :before{box-sizing:inherit;font-family:inherit}@media print{.Header-module--header--3os44{border-bottom:none}}.Header-module--container--1mfIr{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0 0}.Header-module--container--1mfIr:after{clear:both;content:"";display:table}.Header-module--home--1TCPb{color:#000;display:inline-block;float:left;height:1.875rem;margin-bottom:1rem}@media print{.Header-module--home--1TCPb:after{content:none!important}}.Header-module--home--1TCPb:focus{outline:.25rem solid #0092a6}.Header-module--home--1TCPb:visited{color:#000}.Header-module--home--1TCPb .Header-module--icon--4LSt5{height:100%;width:auto}.Header-module--wrapper--2e13D{display:-webkit-flex;display:flex;-webkit-flex-grow:1;flex-grow:1;float:right;-webkit-justify-content:space-between;justify-content:space-between;margin-bottom:1rem;width:50%}@media print{.Header-module--wrapper--2e13D{display:none!important}}.Header-module--wrapper--2e13D:after{clear:both;content:"";display:table}.Header-module--search--2nfnz{-webkit-flex-grow:1;flex-grow:1;float:left;margin-right:1rem;min-width:66.6666666667%}.Header-module--mobileMenuBtn--1LgyL{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:1px solid #222;float:right;font-family:inherit;font-size:110%;height:2.5rem;min-width:4.6875rem;white-space:nowrap}.Header-module--mobileMenuBtn--1LgyL:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Header-module--mobileMenuBtn--1LgyL[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Header-module--account--y72Q4{display:none}@media(max-width:56.24em){.Header-module--home--1TCPb{float:none}.Header-module--wrapper--2e13D{float:none;width:auto}}@media(min-width:56.25em){.Header-module--header--3os44{border-bottom:.25rem solid #fff}.Header-module--container--1mfIr{display:-webkit-flex;display:flex;-webkit-justify-content:space-between;justify-content:space-between}.Header-module--home--1TCPb{height:2.5rem;margin-right:2rem}.Header-module--wrapper--2e13D{-webkit-justify-content:flex-end;justify-content:flex-end}.Header-module--search--2nfnz{margin-right:2rem}.Header-module--mobileMenuBtn--1LgyL{display:none}.Header-module--account--y72Q4{display:block}}.SkipLinks-module--list--1WwLa{list-style:none;margin:0;padding:0}@media print{.SkipLinks-module--list--1WwLa{display:none!important}}.SkipLinks-module--list--1WwLa li{list-style:none;margin:0}.SkipLinks-module--link--hkZw8{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.SkipLinks-module--link--hkZw8:focus{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;left:.25rem;outline:3px solid #0092a6;overflow:visible;padding:.5rem 1rem;position:absolute;top:.25rem;white-space:nowrap;width:auto;z-index:1}.Social-module--wrapper--2nKsd{clear:left}.Social-module--list--E5R5J{list-style:none;margin:0;max-width:100%;padding:0}.Social-module--list--E5R5J li{margin:0 0 .25rem}.Social-module--list--E5R5J svg{margin:-.125rem .25rem 0 0;vertical-align:middle}@media(min-width:37.5em){.Social-module--list--E5R5J li{float:left;margin:0 1rem 0 0}}@media(min-width:56.25em){.Social-module--wrapper--2nKsd{clear:none}.Social-module--wrapper--2nKsd li{float:none;margin:0 0 .25rem}}.Legal-module--wrapper--3AYMO{font-size:.875rem;line-height:1.25rem;background:#393939;padding:1rem 0}.Legal-module--wrapper--3AYMO a{text-decoration:underline}.Legal-module--container--3TTBh{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.Legal-module--menu--1e1Iy{margin:0 0 1rem}@media print{.Legal-module--menu--1e1Iy{display:none!important}}.Legal-module--menu--1e1Iy ul{list-style:none;margin:0;max-width:100%;padding:0}.Legal-module--menu--1e1Iy li{margin:0}.Legal-module--menu--1e1Iy a{display:block}.Legal-module--copyright--34nsI{font-size:.875rem;line-height:1.25rem;margin:0}@media print{.Legal-module--copyright--34nsI{float:none!important;max-width:100%}}@media(min-width:37.5em){.Legal-module--menu--1e1Iy li{display:inline-block;margin-right:1rem}}@media(min-width:75em){.Legal-module--wrapper--3AYMO:after,.Legal-module--wrapper--3AYMO:before{content:" ";display:table}.Legal-module--wrapper--3AYMO:after{clear:both}.Legal-module--menu--1e1Iy{float:left;margin:0}.Legal-module--copyright--34nsI{float:right}}.Services-module--link--2y_1q .Services-module--tooltip--pg3nW{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Services-module--link--2y_1q:focus-visible .Services-module--tooltip--pg3nW{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Services-module--visuallyHidden--t9mfm{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Services-module--wrapper--2qOoE{margin:0 0 2rem}.Services-module--list--3SZQu{list-style:none;margin:0;padding:0}.Services-module--list--3SZQu li{margin:0 0 .25rem}@media(min-width:37.5em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;width:33.3333333333%}}@media(min-width:56.25em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;margin:0;width:25%}}.Pages-module--wrapper--30REl{margin:0 0 2rem}.Pages-module--list--vvSk4{list-style:none;margin:0;padding:0}.Pages-module--list--vvSk4 li{margin:0 0 .25rem}@media(min-width:25em){.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}@media(min-width:37.5em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 0 0 2rem;width:66.6666666667%}}@media(min-width:56.25em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 2rem;width:50%}.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}.Footer-module--link--CGIYk .Footer-module--tooltip--1zoJv{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Footer-module--link--CGIYk:focus-visible .Footer-module--tooltip--1zoJv{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Footer-module--visuallyHidden--3CCnP{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Footer-module--footer--2QrGZ{background:#222;box-sizing:border-box;color:#fff;contain-intrinsic-size:350px;content-visibility:auto;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;margin:2rem 0 0}.Footer-module--footer--2QrGZ a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.Footer-module--footer--2QrGZ a:visited{color:#fff}.Footer-module--footer--2QrGZ a:hover{color:#d6d6d6}.Footer-module--footer--2QrGZ a:focus{outline:.25rem solid #fff;color:#fff}.Footer-module--footer--2QrGZ a:active{color:#d6d6d6}.Footer-module--footer--2QrGZ *,.Footer-module--footer--2QrGZ :after,.Footer-module--footer--2QrGZ :before{box-sizing:inherit}.Footer-module--footer--2QrGZ a{font-weight:400}.Footer-module--container--1iuoB{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0}.Footer-module--container--1iuoB:after,.Footer-module--container--1iuoB:before{content:" ";display:table}.Footer-module--container--1iuoB:after{clear:both}@media print{.Footer-module--container--1iuoB{display:none!important}}.Footer-module--logo--3DGKv{display:block;height:0;margin:0 0 2rem;padding:0 0 29.0496453901px;position:relative;width:80px}.Footer-module--logo--3DGKv svg{display:block;height:100%!important;left:0;position:absolute;top:0;width:100%!important}@media(min-width:56.25em){.Footer-module--logo--3DGKv{margin-bottom:1rem}}.BackToTop-module--wrapper--2Z0EU{margin-top:3rem}@media print{.BackToTop-module--wrapper--2Z0EU{display:none}}.BackToTop-module--nav--1DPZ6{background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}.BackToTop-module--anchor--1Nia6{display:block;line-height:1rem;padding:1rem 0}.BackToTop-module--anchor--1Nia6:visited{color:#005ea5}.BackToTop-module--anchor--1Nia6 svg{-webkit-transition:all .25s ease;transition:all .25s ease}.BackToTop-module--anchor--1Nia6:hover{background:#f4f4f4}.BackToTop-module--anchor--1Nia6:hover svg{-webkit-transform:translateY(-.125rem);transform:translateY(-.125rem)}@supports((position:-webkit-sticky) or (position:sticky)){.BackToTop-module--wrapper--2Z0EU{bottom:0;left:0;margin:0;pointer-events:none;position:absolute;right:0;top:min(100vh,-webkit-calc(100% - 3rem));top:min(100vh,calc(100% - 3rem));width:100%;z-index:99}.BackToTop-module--nav--1DPZ6{position:-webkit-sticky;position:sticky;pointer-events:all;top:-webkit-calc(100vh - 3rem);top:calc(100vh - 3rem);background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-regular.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-regular.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:italic;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-italic.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-italic.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:700;src:local("Lato"),url(../../../../fonts/lato-v17-latin-700.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-700.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:900;src:local("Lato"),url(../../../../fonts/lato-v17-latin-900.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-900.woff) format("woff")}/*! normalize.css v8.0.1 | MIT License | github.com/necolas/normalize.css */html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}main{display:block}h1{font-size:2em;margin:.67em 0}hr{box-sizing:content-box;height:0;overflow:visible}pre{font-family:monospace,monospace;font-size:1em}a{background-color:transparent}abbr[title]{border-bottom:none;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}b,strong{font-weight:bolder}code,kbd,samp{font-family:monospace,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}img{border-style:none}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}fieldset{padding:.35em .75em .625em}legend{box-sizing:border-box;color:inherit;display:table;max-width:100%;padding:0;white-space:normal}progress{vertical-align:baseline}textarea{overflow:auto}[type=checkbox],[type=radio]{box-sizing:border-box;padding:0}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}details{display:block}summary{display:list-item}[hidden],template{display:none}.show-print{display:none!important}@media print{.show-print{display:block!important}}@media print{.hide-print{display:none!important}}@media print{.remove-appended-print-link:after{content:none!important}}@media print{*{background:transparent!important;box-shadow:none!important;color:#000!important;text-shadow:none!important}a,a:visited{text-decoration:underline}}@media print{h1 a:after,h2 a:after,h3 a:after,h4 a:after,h5 a:after,h6 a:after{content:none!important}}@media print{a[href]:after{content:" (" attr(href) ")"}}@media print{abbr[title]:after{content:" (" attr(title) ")"}}@media print{.ir a:after,a[href^="#"]:after,a[href^="javascript:"]:after{content:""}}@media print{blockquote,pre{border:1px solid #999;page-break-inside:avoid}}@media print{thead{display:table-header-group}}@media print{img,tr{page-break-inside:avoid}}@media print{img{max-width:100%!important}}@media print{img:not([alt]),img[alt=""]{display:none!important}}@media print{@page{margin:.5cm}}@media print{h2,h3,p{orphans:3;widows:3}}@media print{h2,h3{page-break-after:avoid}}.clearfix:after,.clearfix:before{content:" ";display:table}.clearfix:after{clear:both}.container{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.container--full{max-width:100%;padding:0 2%;width:auto}html{box-sizing:border-box;font-size:.9375rem;overflow-x:hidden}html *,html :after,html :before{box-sizing:inherit}@media(min-width:56.25em){html{font-size:1.03125rem;font-size:-webkit-calc(.375rem + 1vw);font-size:calc(.375rem + 1vw)}}@media(min-width:75em){html{font-size:1.125rem}}body{background:#f4f4f4;color:#222;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;font-style:normal;line-height:1.5rem;overflow-x:hidden;text-rendering:optimizelegibility}img{max-width:100%}hr{background:0;border:0;border-top:.0625em solid #adadad;margin:2em 0;padding:0}.p,p{font-size:1rem;line-height:1.5rem;font-feature-settings:"kern","onum","liga"}.lead,.p,p{margin-bottom:1rem;margin-top:1rem;font-weight:400;max-width:66ch}.lead{font-size:1.25rem;line-height:1.75rem}code{background:#e9e9e9;border:1px solid #adadad;border-radius:.125em;color:#222;display:inline-block;font-family:Monaco,Menlo,Consolas,Courier New,monospace;margin:0 0 .125em;padding:0 .25em}pre code{background:transparent;border:0;margin:0}.mark,mark{background-color:#fff999;padding:0 .25em}.small,small{font-size:85%}.h6,h6{font-size:1rem}.h5,.h6,h5,h6{line-height:1.5rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h5,h5{font-size:1.125rem}.h4,h4{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h3,h3{font-size:1.75rem;line-height:2rem}.h2,.h3,h2,h3{margin-bottom:1rem;margin-top:2rem;clear:both;font-weight:700;max-width:66ch}.h2,h2{font-size:2.25rem;line-height:2.5rem}.h1,.h2+.h3,.h2+h3,h1,h2+.h3,h2+h3{margin-top:0}.h1,h1{font-size:2.75rem;line-height:3.5rem;margin-bottom:1rem;clear:both;font-weight:900;max-width:66ch}.h1+.h2,.h1+h2,h1+.h2,h1+h2{margin-top:0}a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:visited{color:#4c2c92}a:hover{color:#2e8aca}a:focus{outline:.25rem solid #0092a6;color:#005ea5}a:active{color:#222}.link--inverse{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.link--inverse:visited{color:#fff}.link--inverse:hover{color:#d6d6d6}.link--inverse:focus{outline:.25rem solid #fff;color:#fff}.link--inverse:active{color:#d6d6d6}.inverse-links a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.inverse-links a:visited{color:#fff}.inverse-links a:hover{color:#d6d6d6}.inverse-links a:focus{outline:.25rem solid #fff;color:#fff}.inverse-links a:active{color:#d6d6d6}.list,ol,ul{font-feature-settings:"kern","onum","liga";margin-left:1rem;max-width:66ch;padding:0}.list--unstyled{list-style:none;margin-left:0;max-width:none;padding:0}.list--loose .list__item,.list--loose li{margin-bottom:.25rem}.list--piped{list-style:none;margin-left:0;padding:0}.list--piped .list__item,.list--piped li{display:inline-block;margin-right:-.25rem}.list--piped .list__item a,.list--piped li a{padding:.5rem}.list--piped .list__item:after,.list--piped li:after{border-left:1px solid #004650;content:"\200B";display:inline-block;margin:0 .5em;overflow:hidden;text-indent:-99px;vertical-align:middle;width:0}.list--piped .list__item:first-child a,.list--piped li:first-child a{padding-left:0}.list--piped .list__item:last-child:after,.list--piped li:last-child:after{display:none}.quote{font-size:1.25rem;line-height:1.75rem;border-left:.25em solid #004650;font-weight:400;margin:2rem 0;padding:0 0 0 4rem;position:relative}.quote:before{color:#004650;content:"\201C";display:block;font-family:Arial,sans-serif;font-size:5rem;font-weight:700;left:0;line-height:.8;position:absolute;text-align:center;top:0;width:4rem}@media print{.quote:before{color:#000}}.quote p{font-size:inherit}.quote cite,.quote footer{font-size:1rem;line-height:1.5rem;font-style:normal}table{background:#fff;border:1px solid #adadad;border-collapse:collapse;display:block;margin:0 0 1rem;max-width:100%;overflow-y:hidden;overflow-x:auto;width:100%!important}table th{vertical-align:bottom}table td{vertical-align:top}table td,table th{border:1px solid #adadad;padding:.5rem;text-align:left}table td:first-child,table th:first-child{border-left:0}table td:last-child,table th:last-child{border-right:0}table td p,table th p{margin-top:0}table :not(thead)+tbody tr:first-child th,table tbody tr:first-child th,table thead tr:first-child th{border-top:0}table tbody tr:last-child td{border-bottom:0}table tbody tr:nth-child(2n)>td{background-color:#e9e9e9}html{overflow-x:visible;scroll-behavior:smooth}@media(prefers-reduced-motion){html{scroll-behavior:auto}}body{font-family:Lato,Trebuchet MS,Roboto,Helvetica Neue,Helvetica,Arial,sans-serif;position:relative}.visually-hidden{position:absolute;overflow:hidden;clip:rect(0 0 0 0);height:1px;width:1px;margin:-1px;padding:0;border:0}#content-start:focus{outline:none}footer{margin-top:0!important}@supports((position:-webkit-sticky) or (position:sticky)){.Layout-module--main--1OIFf{position:relative;padding-bottom:4rem}}.stacked-nav{background:#fff;border:1px solid #adadad;margin:0 0 2em}@media print{.stacked-nav{display:none!important}}.stacked-nav__root{font-size:1rem;line-height:1.5rem;border-bottom:1px solid #adadad;font-weight:700;margin:0;max-width:none;position:relative;text-decoration:none}.stacked-nav__root a{color:#222}.stacked-nav__root--no-link{padding:.5em}.stacked-nav__hint{color:#222;display:block}.stacked-nav__hint :active{color:#fff}.stacked-nav__list{list-style:none;margin:0;max-width:100%;padding:0}.stacked-nav__list-item{border-top:1px solid #adadad}.stacked-nav__content-wrapper{display:block}.stacked-nav a{color:#005ea5;display:block;padding:.5em;position:relative;text-decoration:none}.stacked-nav a[aria-current=page],.stacked-nav a[aria-current=true]{background:#e9e9e9;font-weight:700}.stacked-nav a[aria-current=page]:before,.stacked-nav a[aria-current=true]:before{background:#004650;content:"";display:block;height:100%;left:0;position:absolute;top:0;width:.25em}.stacked-nav a:hover{background:#d6d6d6}.stacked-nav a:active{background:#004650;color:#fff}.stacked-nav a:active span{color:#fff}.stacked-nav__nested{list-style:none;margin:0;padding:0}.stacked-nav__nested .stacked-nav__content-wrapper{padding-left:1rem!important}.stacked-nav__nested ul .stacked-nav__content-wrapper{padding-left:2rem!important}.TopicChaptersMenu-module--toggleButton--2MGXA{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:#e9e9e9;border:1px solid #adadad;color:#005ea5;cursor:pointer;display:block;margin:0 0 2rem;padding:1rem 2rem 1rem .5rem;position:relative;text-align:left;width:100%}.TopicChaptersMenu-module--toggleButton--2MGXA:focus{outline:.25rem solid #0092a6;z-index:1}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=false]+.stacked-nav{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]{border-bottom:0;margin:0}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]+.stacked-nav{display:block}@media(min-width:37.5em){.TopicChaptersMenu-module--toggleButton--2MGXA{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded]+.stacked-nav{display:block}}.TopicChaptersMenu-module--icon--27uSj{color:#005ea5;right:.5rem;position:absolute;top:50%;-webkit-transform:translateY(-50%);transform:translateY(-50%)}.ChapterContents-module--wrapper--3ONbu{position:relative}.ChapterContents-module--printBtn--Rk_Zs{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;bottom:100%;cursor:pointer;display:none;padding:0}.ChapterContents-module--printBtn--Rk_Zs:visited{color:#4c2c92}.ChapterContents-module--printBtn--Rk_Zs:hover{color:#2e8aca}.ChapterContents-module--printBtn--Rk_Zs:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterContents-module--printBtn--Rk_Zs:active{color:#222}.ChapterContents-module--printBtn--Rk_Zs svg{font-size:1.25rem;line-height:1.75rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterContents-module--printBtn--Rk_Zs:hover svg{color:#2e8aca}@media(min-width:37.5em){.ChapterContents-module--wrapper--3ONbu:after,.ChapterContents-module--wrapper--3ONbu:before{content:" ";display:table}.ChapterContents-module--wrapper--3ONbu:after{clear:both}.ChapterContents-module--menu--3Epka{float:left;margin-right:1rem;width:-webkit-calc(25% - .5rem);width:calc(25% - .5rem)}.ChapterContents-module--landing--3klSq,.ChapterContents-module--onThisPage--1333P{float:right;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + .5rem);overflow:hidden;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}}@media(min-width:56.25em){.ChapterContents-module--printBtn--Rk_Zs{display:block;margin-bottom:3rem;position:absolute;right:0}.ChapterContents-module--menu--3Epka{margin-right:2rem;width:-webkit-calc(25% - 1rem);width:calc(25% - 1rem)}.ChapterContents-module--landing--3klSq{width:-webkit-calc(75% - 1rem);width:calc(75% - 1rem)}.ChapterContents-module--onThisPage--1333P{position:-webkit-sticky;position:sticky;top:0;width:-webkit-calc(16.66667% - 1rem);width:calc(16.66667% - 1rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + 1rem);width:-webkit-calc(58.33333% - 2rem);width:calc(58.33333% - 2rem)}}@media print{.ChapterContents-module--menu--3Epka,.ChapterContents-module--onThisPage--1333P,.ChapterContents-module--printBtn--Rk_Zs{display:none}.ChapterContents-module--body--1XBoo{width:100%}}.ChapterBody-module--wrapper--2HCfk>.visually-hidden:first-child+*>:first-child{margin-top:0}.ChapterBody-module--wrapper--2HCfk h2:focus,.ChapterBody-module--wrapper--2HCfk h3:focus,.ChapterBody-module--wrapper--2HCfk h4:focus,.ChapterBody-module--wrapper--2HCfk h5:focus,.ChapterBody-module--wrapper--2HCfk h6:focus{outline:0!important}.ChapterBody-module--basisWrapper--3JBM_{border:1px solid #adadad;margin-top:1rem;max-width:66ch}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-top:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK{padding:0 1rem 1rem}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK>:last-child{margin-bottom:0}.ChapterBody-module--headerWrapper--qSIFw{padding:1rem;position:relative}.ChapterBody-module--toggleBtn--3g0p7{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;cursor:pointer;display:block;margin-top:-.5rem;padding:0}.ChapterBody-module--toggleBtn--3g0p7:visited{color:#4c2c92}.ChapterBody-module--toggleBtn--3g0p7:hover{color:#2e8aca}.ChapterBody-module--toggleBtn--3g0p7:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterBody-module--toggleBtn--3g0p7:active{color:#222}.ChapterBody-module--toggleBtn--3g0p7:after{content:"";height:100%;left:0;position:absolute;top:0;width:100%}.ChapterBody-module--toggleBtn--3g0p7 svg{font-size:1.125rem;line-height:1.5rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterBody-module--toggleBtn--3g0p7:hover svg{color:#2e8aca}.ChapterBody-module--body--2n0CK[aria-hidden=true]{display:none}@media print{.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-bottom:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK[aria-hidden=true]{display:block}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--toggleBtn--3g0p7{display:none}}.ChapterOnThisPage-module--wrapper--2zc7n{margin-bottom:2rem}.ChapterOnThisPage-module--heading--2SdDN{margin-top:0}.ChapterOnThisPage-module--rootList--2II70{list-style:disc}.ChapterOnThisPage-module--subList--Pwxy9{list-style:circle}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:none}@media(min-width:56.25em){.ChapterOnThisPage-module--heading--2SdDN{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:0}@supports((position:-webkit-sticky) or (position:sticky)){.ChapterOnThisPage-module--rootList--2II70 a[aria-current=location]{font-weight:700}.ChapterOnThisPage-module--rootList--2II70 a:focus+.ChapterOnThisPage-module--subList--Pwxy9{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--subList--Pwxy9{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.ChapterOnThisPage-module--subList--Pwxy9:focus-within{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--expandedSubList--1m1WN{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:list-item}}}</style><link rel="sitemap" type="application/xml" href="../../../../sitemap.xml"/><title data-react-helmet="true">Scenario: Progestogen-only injectables | Management | Contraception - progestogen-only methods | CKS | NICE</title><link data-react-helmet="true" rel="search" type="application/opensearchdescription+xml" href="../../../../opensearch.xml" title="CKS"/><link data-react-helmet="true" rel="icon" href="../../../../favicon.ico"/><link data-react-helmet="true" rel="canonical" href="index.html"/><meta data-react-helmet="true" name="description" content="Covers the use of the progestogen-only injectable, including the available products; when to start it; the efficacy; how to manage common problems (such as late injection); the advantages, disadvantages, risks, possible adverse effects and key drug interactions; and follow up requirements for this method of contraception."/><meta data-react-helmet="true" property="og:description" content="Covers the use of the progestogen-only injectable, including the available products; when to start it; the efficacy; how to manage common problems (such as late injection); the advantages, disadvantages, risks, possible adverse effects and key drug interactions; and follow up requirements for this method of contraception."/><meta data-react-helmet="true" property="og:url" content="https://cks.nice.org.uk/topics/contraception-progestogen-only-methods/management/progestogen-only-injectables/"/><meta data-react-helmet="true" property="og:locale" content="en_GB"/><meta data-react-helmet="true" property="og:type" content="website"/><meta data-react-helmet="true" property="og:title" content="Scenario: Progestogen-only injectables | Management | Contraception - progestogen-only methods | CKS | NICE"/><meta data-react-helmet="true" property="og:image" content="https://cks.nice.org.uk/open-graph-image.png"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="630"/><meta data-react-helmet="true" name="twitter:card" content="summary"/><meta data-react-helmet="true" name="twitter:image" content="https://cks.nice.org.uk/twitter-summary-image.png"/><meta data-react-helmet="true" name="twitter:image:alt" content="NICE and CKS logos"/><meta data-react-helmet="true" name="twitter:site" content="@NICEcomms"/><meta data-react-helmet="true" name="twitter:creator" content="@NICEcomms"/><meta data-react-helmet="true" name="theme-color" content="#004650"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-54QC4NL');</script><link rel="manifest" href="../../../../manifest.webmanifest" crossorigin="anonymous"/><meta name="theme-color" content="#004650"/><link rel="apple-touch-icon" sizes="48x48" href="../../../../icons/icon-48x48.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="72x72" href="../../../../icons/icon-72x72.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="96x96" href="../../../../icons/icon-96x96.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="144x144" href="../../../../icons/icon-144x144.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="192x192" href="../../../../icons/icon-192x192.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="256x256" href="../../../../icons/icon-256x256.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="384x384" href="../../../../icons/icon-384x384.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="512x512" href="../../../../icons/icon-512x512.png@v=28734348209eeeae5c03a37867f1beb1"/><link as="script" rel="preload" href="../../../../webpack-runtime-28c424ef71f39faedaf0.js"/><link as="script" rel="preload" href="../../../../framework-34da02e39e1f104d9937.js"/><link as="script" rel="preload" href="../../../../app-53a71c38b210970893c4.js"/><link as="script" rel="preload" href="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js"/><link as="script" rel="preload" href="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js"/><link as="script" rel="preload" href="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"/><link as="fetch" rel="preload" href="../../../../page-data/topics/contraception-progestogen-only-methods/management/progestogen-only-injectables/page-data.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/sq/d/3666801979.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/app-data.json" crossorigin="anonymous"/><script src="https://cdn.nice.org.uk/cookie-banner/cookie-banner.min.js" type="text/javascript" async=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54QC4NL" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><div><div class="Header-module--header--3os44"><header aria-label="Site header"><ul class="SkipLinks-module--list--1WwLa" aria-label="Accessibility links"><li><a href="index.html#content-start" class="SkipLinks-module--link--hkZw8">Skip to content</a></li><li><a href="https://www.nice.org.uk/accessibility" class="SkipLinks-module--link--hkZw8">Accessibility help</a></li></ul><div class="Header-module--container--1mfIr"><a href="https://www.nice.org.uk/" aria-label="Home" class="Header-module--home--1TCPb"><svg viewBox="0 0 4616 512" fill="none" class="Header-module--icon--4LSt5" aria-hidden="true" focusable="false"><path d="M1626 44v175h-22L1497 71v148h-19V44h22l107 147V44h19zm130 154a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-35 18-48 11-14 27-20 47-20 19 0 34 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm109 16V104h-27V87h27V40h19v47h30v17h-30v115h-19zm88-180v26h-21V39h21zm-20 48h20v132h-20V87zm107-2c20 0 35 6 48 20 11 12 17 28 17 48 0 19-6 36-17 48a61 61 0 01-48 20c-19 0-35-7-47-20a69 69 0 01-17-48c0-20 5-36 17-48 12-14 28-20 47-20zm0 118c14 0 25-5 34-15 7-9 11-21 11-35s-4-26-11-35c-9-10-20-15-34-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm107-116v21c5-7 11-12 18-17 6-4 14-6 23-6 8 0 16 1 22 4 6 2 12 6 17 11 10 10 16 24 16 42v77h-20v-76c0-13-3-22-10-29-7-8-16-11-26-11a38 38 0 00-40 40v76h-19V87h19zm222 111a52 52 0 01-46 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 5-35 17-48 12-14 27-20 47-20 19 0 35 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm114 16h-19V34h19v185zm108 0h-19V44h19v175zm55-132v21c5-7 10-12 17-17 7-4 15-6 23-6 9 0 17 1 23 4 6 2 12 6 16 11 11 10 16 24 16 42v77h-19v-76c0-13-4-22-10-29-7-8-16-11-27-11a38 38 0 00-39 40v76h-19V87h19zm202 35c-2-13-13-20-33-20s-30 6-30 19c0 5 2 9 6 12 5 2 10 5 16 6l21 5 21 7c7 2 12 6 16 11 5 5 7 11 7 19 0 13-5 23-15 30-9 7-22 10-38 10-18 0-32-4-42-13-9-8-14-18-15-31h20c2 13 8 21 21 25l13 2 13-1 11-3c8-3 12-9 12-17 0-5-2-9-6-12s-10-6-16-7l-21-5-21-7c-7-2-12-6-16-10-4-5-6-11-6-19 0-12 4-22 12-28 9-7 22-10 39-10 15 0 28 4 37 11 8 7 12 16 14 26h-20zm60 97V104h-26V87h26V40h20v47h30v17h-30v115h-20zm89-180v26h-21V39h21zm-21 48h20v132h-20V87zm65 132V104h-26V87h26V40h20v47h30v17h-30v115h-20zm162 0v-21c-4 7-10 12-17 16-7 5-14 7-23 7s-16-1-22-4c-7-2-12-6-17-11a57 57 0 01-16-42V87h20v76c0 12 3 22 10 29 6 7 15 11 26 11a39 39 0 0039-40V87h20v132h-20zm65 0V104h-26V87h26V40h20v47h30v17h-30v115h-20zm124-16c17 0 30-7 37-22h22c-5 12-12 22-22 29-9 7-22 11-38 11-19 0-35-7-47-20a68 68 0 01-18-48c0-20 5-36 17-48 12-14 28-20 47-20 20 0 35 6 48 20 11 12 17 28 17 48v8h-109c1 12 6 22 14 30s19 12 32 12zm-2-100c-12 0-22 4-30 11s-12 17-14 28h88c-1-11-6-21-14-28s-18-11-30-11zm195-52c-9 0-16 2-21 6-4 4-7 11-7 20v10h30v17h-30v115h-19V104h-23V87h23V75c0-14 4-25 12-32 9-7 21-11 36-11h1v19h-2zm75 34c19 0 35 6 47 20 12 12 18 28 18 48 0 19-6 36-18 48a61 61 0 01-47 20c-19 0-35-7-47-20a69 69 0 01-18-48c0-20 6-36 18-48 12-14 28-20 47-20zm0 118c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm156-118v20h-2c-14 0-25 5-34 17-9 11-13 24-13 39v58h-19V87h19v32c4-13 13-23 27-30 6-3 13-4 21-4h1zM1617 293v175h-19v-78h-101v78h-19V293h19v78h101v-78h19zm91 159c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c1 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm187 95a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-36 18-49 11-13 27-19 47-19 19 0 34 7 45 23v-21h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm114 16h-19V283h19v185zm46 0V353h-27v-17h27v-48h19v48h30v17h-30v115h-19zm87-185v73l17-16c7-4 15-6 24-6 8 0 16 1 22 3a58 58 0 0133 54v77h-20v-77c0-12-3-21-10-29-7-7-16-10-26-10a39 39 0 00-40 40v76h-19V283h19zm280 164a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm109-116v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 11 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10a39 39 0 00-39 40v76h-19V336h19zm222 111a52 52 0 01-47 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-74h19v185h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm233-1a56 56 0 0053-36h21c-6 17-15 30-28 39a82 82 0 01-50 16c-25 0-46-9-61-26a92 92 0 01-22-64c0-25 7-46 22-63 15-18 36-26 61-26a78 78 0 0178 54h-21c-4-11-11-19-20-25-10-7-20-10-33-10-12 0-22 2-30 5-9 4-15 9-21 15a73 73 0 00-17 50c0 21 6 37 17 50 12 14 29 21 51 21zm198-4a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 48-19 19 0 34 7 45 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm163-118v19h-2c-14 0-26 6-34 18-9 10-13 23-13 39v58h-19V336h19v32c4-14 13-24 27-30 6-3 13-4 21-4h1zm73 118c18 0 31-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-19 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 18-49s27-19 47-19c19 0 35 6 47 19s17 29 17 49v8h-109c2 12 7 22 15 30s19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm162-40v59h96v19h-96v59h108v19h-127V293h127v19h-108zm189 88l51 68h-25l-37-54-37 54h-25l51-68-48-64h25l34 50 33-50h25l-47 64zm120 52c9 0 16-3 23-7 6-5 11-11 14-19h21c-4 13-12 24-22 32-11 8-24 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19a60 60 0 0161 44h-20c-3-8-8-15-14-19-7-5-14-7-23-7-8 0-15 1-21 4-6 2-10 6-14 10-9 10-13 22-13 36s4 26 13 35c8 10 20 15 35 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-20 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 13-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm105 116h-19V283h19v185zm51 0h-20V283h20v185zm89-16c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c2 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm105-16v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 12 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10s-20 3-28 11c-7 7-11 17-11 29v76h-19V336h19zm185 116a40 40 0 0037-26h21c-4 13-12 24-22 32-11 8-25 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19c15 0 29 4 40 12 10 8 18 18 22 31h-21c-3-7-8-14-15-18-6-5-13-7-22-7-8 0-15 1-21 4-6 2-11 6-15 10-8 10-12 22-12 36s4 26 12 35c9 10 21 15 36 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 18 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-15 28h89c-2-11-6-21-14-28-8-8-18-11-30-11zM412 454c0 16-7 19-18 19h-53c-11 0-20-4-27-13L130 213h-2v242c0 13-6 18-18 18H52c-14 0-20-3-20-18V62c0-16 7-19 20-19h52c13 0 19 3 26 13l184 248h1V61c0-14 7-18 19-18h60c16 0 17 8 17 19v392h1zm197 4c0 7-5 14-14 14h-71c-9 0-14-7-14-14V56c0-8 5-15 14-15h71c9 0 14 7 14 14v403zm415-380l-18 52c-2 6-5 9-9 9l-8-2c-33-16-58-21-87-21-65 0-106 49-106 140 0 98 47 140 107 140 29 0 55-5 84-17l9-3c6 0 9 3 11 10l16 46 2 10c0 6-3 11-12 14-42 16-77 24-125 24-131 0-197-87-197-221S772 32 896 32c45 0 82 9 118 25 9 4 12 8 12 12l-2 9zm336-37c13 0 17 6 16 15l-6 50c-1 13-9 15-24 15h-149v93h140c14 0 19 7 19 17v45c0 12-7 18-18 18h-141v98h161c11 0 18 5 18 17v46c0 11-6 17-17 17h-240c-14 0-21-4-21-19V59c0-11 6-18 16-18h246z" fill="currentColor"></path></svg></a><div class="Header-module--wrapper--2e13D"><div class="Header-module--search--2nfnz"><form id="global-nav-search-form" role="search" action="https://cks.nice.org.uk/search" class="Search-module--search--2wNll"><label class="Search-module--label--1rrog" for="autocomplete">Search CKS…</label><div class="Autocomplete-module--ac--2PqiF"><div class="autocomplete__wrapper"><input type="search" id="autocomplete" name="q" class="autocomplete__input autocomplete__input--default" placeholder="Search CKS…" data-hj-allow="" maxLength="512" value=""/></div></div><button class="Search-module--button--2FbnI" type="submit" aria-label="Perform search"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="Search-module--icon--2JB42" aria-hidden="true" focusable="false"><path d="M83.784 476.472L197.112 363.16c30.144 20.32 65.056 30.528 100.032 30.528 45.904 0 91.776-17.488 126.8-52.528 70.064-70.064 70.064-183.584 0-253.616C388.936 52.504 343.048 35 297.144 35c-45.904 0-91.808 17.504-126.848 52.528-61.696 61.696-68.976 157.12-21.968 226.864L35 427.752l48.784 48.72zm213.36-137.952c-33.168 0-64.352-12.896-87.792-36.368-48.416-48.448-48.416-127.2 0-175.616 23.44-23.44 54.64-36.352 87.792-36.352s64.336 12.912 87.776 36.368c23.44 23.456 36.384 54.64 36.384 87.792s-12.928 64.352-36.384 87.792c-23.456 23.472-54.624 36.368-87.776 36.368v.016z" fill="currentColor"></path></svg></button></form></div><button class="Header-module--mobileMenuBtn--1LgyL" id="header-menu-button" type="button" aria-controls="header-menu" aria-expanded="false" aria-haspopup="menu" aria-label="Expand site menu">Menu</button></div></div><div id="header-menu" class="Nav-module--wrapper--2_xng Nav-module--wrapperWithSubLinks--3PUfX"><nav class="Nav-module--nav--2aQpa" aria-label="primary navigation"><div class="Nav-module--menuWrapper--2fp8S"><ul class="Nav-module--menuList--264L-" aria-labelledby="header-menu-button"><li><a href="https://pathways.nice.org.uk/" class="Nav-module--link--3JzDA">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Nav-module--link--3JzDA">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Nav-module--link--3JzDA">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Nav-module--link--3JzDA">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary">BNF<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Nav-module--link--3JzDA"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">Clinical Knowledge Summaries</span></a><div class="SubNav-module--wrapper--yAXWY"><ul class="SubNav-module--list--1K9bK" aria-label="CKS links"><li class="SubNav-module--imageLink--3xwIS"><a href="../../../../index.html" class="SubNav-module--link--39i23" aria-label="CKS - Home"><img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIG92ZXJmbG93PSJ2aXNpYmxlIiB2aWV3Qm94PSIwIDAgMjI2Ljc3IDExOS4wNiI+CiAgPHN0eWxlPgogICAgLnN0MHtmaWxsOiMyNzQ5NTF9CiAgPC9zdHlsZT4KICA8cGF0aCBkPSJNMTY4Ljk2IDIwLjk3Yy0zLjk0IDEuMjgtMy44NCAxLjI4IDUuOSAxLjg3IDUuNDEuMyAxMi40IDEuMjggMTUuNTQgMi4yN2w1LjYxIDEuODd2OC43OGMwIDEwLjA2IDEuMTggOS4zNy0xMC4zMyA2LjIxLTYuNTktMS43Ny0xOC4zLTIuMDctMjEuMjUtLjU5LTQuMzMgMi4zNy0uNjkgNi4yMSA2Ljk4IDcuNCA5LjM1IDEuNDggMTkuMTggNS4yMyAyMi4zMyA4LjU4IDQuNDMgNC43MyA1LjUxIDcuNDkgNS41MSAxMy42MSAwIDE0LjQtOS45NCAyMi4xOS0yOS44MSAyMy4zN2wtOS4zNS41OSA0LjQzIDIuMDdjMy42NCAxLjU4IDYuNDkgMS45NyAxNS43NCAyLjA3IDExLjAyIDAgMTEuNjEtLjEgMTguMi0zLjM1IDguNTItNC4xNCAxNS4zOS0xMS4wNiAxOS40OC0xOS42MiAyLjg1LTYuMDIgMy4xNS03LjQgMy4xNS0xNi40N3MtLjMtMTAuNDUtMy4xNS0xNi40N2MtNC4wMS04LjUzLTEwLjgyLTE1LjQyLTE5LjI4LTE5LjUyLTUuOS0yLjg2LTcuNzctMy4yNS0xNi4yMy0zLjU1LTUuOTktLjMtMTEuMDEuMDktMTMuNDcuODh6TTM0LjE4IDI0LjAzYy0xMC45MiAyLjc2LTE5Ljg3IDkuNjYtMjQuNjkgMTkuMDMtMi42NiA1LjMyLTIuODUgNi41MS0yLjg1IDE2LjU3IDAgOS44Ni4yIDExLjM0IDIuNjYgMTUuNzggNy4xOCAxMy41MSAyMi4xNCAyMC4yMSA0Mi4xMSAxOC44MyA0LjA2LS4yNiA4LjExLS43OSAxMi4xLTEuNThsMy42NC0xLjA4VjgyLjdjMC03Ljk5LS4yLTguODctMS42Ny04LjM4LTEwLjcyIDMuMjUtMjMuNDEgMy40NS0yOS40Mi41OS0yLjE3LTEuMS00LjExLTIuNi01LjcxLTQuNDQtMy45NC02LjAyLTMuOTQtMTcuNTUuMS0yMy4wNyAxLjgtMiAzLjkzLTMuNjcgNi4zLTQuOTMgMy42NC0yLjA3IDUuNTEtMi40NyAxMi4yLTIuMzcgNC4yNC4wNyA4LjQ2LjYgMTIuNTkgMS41OGw0LjcyIDEuNDgtLjMtOC45Ny0uMy05LjA3LTQuOTItMS4wOGMtNi40OS0xLjU5LTIwLjM2LTEuNDktMjYuNTYtLjAxek03Ni45OCA1OC42NHYzNS4wMWgyMC42NlY3MC40N2wxMS42MSAxMS42NCAxMS41MSAxMS41NGgyNy40NWwtMTcuMjItMTcuMjZjLTkuNDQtOS41Ny0xNy4yMi0xNy42NS0xNy40MS0xOC4xNC0uMi0uNDkgNi43OS04LjE4IDE1LjU0LTE3LjE2czE1Ljc0LTE2LjQ3IDE1Ljc0LTE2Ljg2LTUuOC0uNTktMTIuOTktLjU5aC0xMi45OWwtMTAuNjIgMTEuMDQtMTAuNTMgMTEuMTRWMzQuNjhsLS4xLTExLjA0SDc2Ljk4djM1eiIgY2xhc3M9InN0MCIvPgogIDxwYXRoIGQ9Ik0xMzkuNTQgNTIuMzNjLS44OSA0LjgzLS42OSAxMy4xMi40OSAxNi40Ny43OSAyLjI3IDIuMDcgMy40NSA1LjEyIDQuNTQgNy42NyAyLjc2IDEyIDMuNTUgMTkuODcgMy41NSA4LjY2IDAgMTIuNTktMS4zOCAxMy4wOC00LjU0LjM5LTIuNTYtMS45Ny0zLjU1LTE0LjI2LTYuMjEtNC4wNS0uODItOC4wNC0xLjk4LTExLjktMy40NS0zLjY0LTEuODctOC44NS03Ljc5LTkuNjQtMTAuOTUtLjc5LTMuMzYtMS45Ny0zLjA2LTIuNzYuNTl6TTcuNTggNDcuM3MtNC4zOSAxMi40Ny4xMyAyNC4zMSIgY2xhc3M9InN0MCIvPgogIDxwYXRoIGZpbGw9Im5vbmUiIGQ9Ik0wIDBoMjI2Ljc3djExOS4wNkgweiIvPgo8L3N2Zz4K" class="SubNav-module--image--uq-a2" alt=""/></a></li><li><a href="../../../index.html" class="SubNav-module--link--39i23" aria-label="Health topics A to Z">Health topics A to Z</a></li><li><a href="../../../../specialities/index.html" class="SubNav-module--link--39i23" aria-label="Specialities">Specialities</a></li><li><a href="../../../../whats-new/index.html" class="SubNav-module--link--39i23" aria-label="What&#x27;s new">What&#x27;s new</a></li><li><a href="../../../../about/index.html" class="SubNav-module--link--39i23" aria-label="About CKS">About CKS</a></li></ul></div></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Nav-module--link--3JzDA">Journals and databases</a></li></ul></div></nav></div></header><aside class="CoronaMessage-module--wrapper--zRiaV" aria-label="COVID-19 Notice"><div class="CoronaMessage-module--container--36Biz"><p>Read about<!-- --> <a href="https://www.nice.org.uk/covid-19">our approach to COVID-19</a></p></div></aside></div></div><main class="Layout-module--main--1OIFf" id="content-start"><div class="container"><nav aria-label="Breadcrumbs" role="navigation"><ol class="breadcrumbs"><li class="breadcrumbs__crumb"><a href="https://www.nice.org.uk/">NICE</a></li><li class="breadcrumbs__crumb"><a href="../../../../index.html">CKS</a></li><li class="breadcrumbs__crumb"><a href="../../../index.html">Health topics A to Z</a></li><li class="breadcrumbs__crumb"><a href="../../index.html">Contraception - progestogen-only methods</a></li><li class="breadcrumbs__crumb"><a href="../index.html">Management</a></li><li class="breadcrumbs__crumb"><span>Scenario: Progestogen-only injectables</span></li></ol></nav><script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.nice.org.uk/","name":"NICE"}},{"@type":"ListItem","position":2,"item":{"@id":"/","name":"CKS"}},{"@type":"ListItem","position":3,"item":{"@id":"/topics/","name":"Health topics A to Z"}},{"@type":"ListItem","position":4,"item":{"@id":"/topics/contraception-progestogen-only-methods/","name":"Contraception - progestogen-only methods"}},{"@type":"ListItem","position":5,"item":{"@id":"/topics/contraception-progestogen-only-methods/management/","name":"Management"}},{"@type":"ListItem","position":6,"item":{"name":"Scenario: Progestogen-only injectables"}}]}</script><div class="page-header"><h1 class="page-header__heading"><span class="page-header__pre-heading">Contraception - progestogen-only methods: </span><span>Scenario: Progestogen-only injectables</span></h1><p class="page-header__lead"><span>Last revised in November 2019</span></p></div><p class="visually-hidden">Covers the use of the progestogen-only injectable, including the available products; when to start it; the efficacy; how to manage common problems (such as late injection); the advantages, disadvantages, risks, possible adverse effects and key drug interactions; and follow up requirements for this method of contraception.</p><div class="ChapterContents-module--wrapper--3ONbu"><div class="ChapterContents-module--menu--3Epka"><nav class="stacked-nav" aria-label="Contraception - progestogen-only methods chapters"><ul class="stacked-nav__list"><li class="stacked-nav__list-item" data-tracking="Summary"><a aria-current="false" href="../../index.html"><span class="stacked-nav__content-wrapper">Summary</span></a></li><li class="stacked-nav__list-item" data-tracking="Have I got the right topic?"><a aria-current="false" href="../../have-i-got-the-right-topic/index.html"><span class="stacked-nav__content-wrapper">Have I got the right topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="How up-to-date is this topic?"><a aria-current="false" href="../../how-up-to-date-is-this-topic/index.html"><span class="stacked-nav__content-wrapper">How up-to-date is this topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="Goals and outcome measures"><a aria-current="false" href="../../goals-outcome-measures/index.html"><span class="stacked-nav__content-wrapper">Goals and outcome measures</span></a></li><li class="stacked-nav__list-item" data-tracking="Background information"><a aria-current="false" href="../../background-information/index.html"><span class="stacked-nav__content-wrapper">Background information</span></a></li><li class="stacked-nav__list-item" data-tracking="Management"><a aria-current="false" href="../index.html"><span class="stacked-nav__content-wrapper">Management</span></a><ul class="stacked-nav__nested"><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Progestogen-only pill"><a aria-current="false" href="../progestogen-only-pill/index.html"><span class="stacked-nav__content-wrapper">Scenario: Progestogen-only pill</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Progestogen-only implant"><a aria-current="false" href="../progestogen-only-implant/index.html"><span class="stacked-nav__content-wrapper">Scenario: Progestogen-only implant</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Progestogen-only injectables"><a aria-current="true" class="" href="index.html"><span class="stacked-nav__content-wrapper">Scenario: Progestogen-only injectables</span></a></li></ul></li><li class="stacked-nav__list-item" data-tracking="Supporting evidence"><a aria-current="false" href="../../supporting-evidence/index.html"><span class="stacked-nav__content-wrapper">Supporting evidence</span></a></li><li class="stacked-nav__list-item" data-tracking="How this topic was developed"><a aria-current="false" href="../../how-this-topic-was-developed/index.html"><span class="stacked-nav__content-wrapper">How this topic was developed</span></a></li><li class="stacked-nav__list-item" data-tracking="References"><a aria-current="false" href="../../references/index.html"><span class="stacked-nav__content-wrapper">References</span></a></li></ul></nav></div><div class="ChapterContents-module--onThisPage--1333P"><nav class="ChapterOnThisPage-module--wrapper--2zc7n" aria-labelledby="on-this-page"><h2 class="ChapterOnThisPage-module--heading--2SdDN" id="on-this-page">On this page</h2><ol class="ChapterOnThisPage-module--rootList--2II70" aria-label="Jump links to section on this page"><li><a href="index.html#starting-a-progestogen-only-injectable">Starting a progestogen-only injectable</a><ol aria-label="Sections within Starting a progestogen-only injectable" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#assessment">Assessment</a></li><li class=""><a href="index.html#when-to-start">When to start</a></li><li class=""><a href="index.html#types-of-progestogen-only-injectable">Types of progestogen-only injectable</a></li><li class=""><a href="index.html#mechanism-of-action">Mechanism of action</a></li><li class=""><a href="index.html#choice-of-progestogen-only-injectable">Choice of progestogen-only injectable</a></li><li class=""><a href="index.html#when-to-start-amenorrhoea">When to start - Amenorrhoea</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-272">Basis for recommendation</a></li></ol></li><li><a href="index.html#information-advice">Information and advice</a><ol aria-label="Sections within Information and advice" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#late-repeat">Late repeat</a></li><li class=""><a href="index.html#pregnancy">Pregnancy</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-159">Basis for recommendation</a></li></ol></li><li><a href="index.html#advantages-disadvantages">Advantages and disadvantages</a><ol aria-label="Sections within Advantages and disadvantages" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-0b5">Basis for recommendation</a></li></ol></li><li><a href="index.html#risks-adverse-effects">Risks and adverse effects</a><ol aria-label="Sections within Risks and adverse effects" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-5e6">Basis for recommendation</a></li><li class=""><a href="index.html#menstrual-irregularities">Menstrual irregularities</a></li></ol></li><li><a href="index.html#drug-interactions">Drug interactions</a><ol aria-label="Sections within Drug interactions" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-095">Basis for recommendation</a></li></ol></li><li><a href="index.html#efficacy">Efficacy</a><ol aria-label="Sections within Efficacy" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-795">Basis for recommendation</a></li></ol></li><li><a href="index.html#follow-up">Follow up</a><ol aria-label="Sections within Follow up" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#duration-of-use">Duration of use</a></li><li class=""><a href="index.html#timing-of-repeat-injections">Timing of repeat injections</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-878">Basis for recommendation</a></li></ol></li></ol></nav></div><div class="ChapterContents-module--body--1XBoo"><section aria-labelledby="progestogen-only-injectables" class="ChapterBody-module--wrapper--2HCfk "><h2 id="progestogen-only-injectables" class="visually-hidden">Scenario: Progestogen-only injectables</h2><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item e7d7effc-a899-443e-b0ea-ebe514f83746 --><!-- begin field d0c34053-a3f4-455f-94c6-acbc015798d1 --><p>From age 13 years to 60 years (Female).</p><!-- end field d0c34053-a3f4-455f-94c6-acbc015798d1 --><!-- end item e7d7effc-a899-443e-b0ea-ebe514f83746 --></div><section aria-labelledby="starting-a-progestogen-only-injectable" class="ChapterBody-module--wrapper--2HCfk "><h3 id="starting-a-progestogen-only-injectable">Starting a progestogen-only injectable</h3><section aria-labelledby="assessment" class="ChapterBody-module--wrapper--2HCfk "><h4 id="assessment">How should I assess a woman before providing her with a progestogen-only injectable?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 12944b02-6d71-4864-9d25-a7a700e6f605 --><!-- begin field d7982d25-3fd0-4128-8bc3-a7a700e6f8f6 --><ul><li>For information on assessing a woman considering starting a progestogen-only injectable, see the section on <a class="topic-reference external-reference" href="../../../contraception-assessment/management/assessment-for-specific-contraceptive-methods/index.html#progestogen-only-injectable">Progestogen-only injectable</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-assessment/index.html">Contraception - assessment</a>.</li></ul><!-- end field d7982d25-3fd0-4128-8bc3-a7a700e6f8f6 --><!-- end item 12944b02-6d71-4864-9d25-a7a700e6f605 --></div></section><section aria-labelledby="when-to-start" class="ChapterBody-module--wrapper--2HCfk "><h4 id="when-to-start">When should I start a progestogen-only injectable?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 08c75333-5285-48ff-8192-f303c4aa83af --><!-- begin field 6ebe6b3c-8bb7-4f01-8cdb-30b706a6f969 --><ul><li><strong>If the woman is not currently using a regular method of contraception:</strong><ul><li>Ideally, give the first injection up to, and including day 5 after the start of menstrual bleeding. <ul><li>No additional contraception is required.</li></ul></li><li>If this is not possible, give the progestogen-only injectable at any other time in the menstrual cycle provided it is reasonably certain that the woman is not pregnant and there is no risk of conception.<ul><li>Advise the woman to avoid intercourse or use a barrier method of contraception (such as condoms) for 7 days.</li></ul></li></ul></li><li><strong>If the woman is starting the injectable after oral emergency contraception:</strong><ul><li>Ideally offer a bridging method of contraception (such as combined hormonal contraception or progestogen-only pills) until pregnancy can be excluded. However if this is not suitable or acceptable:<ul><li>For levonorgestrel, give the progestogen-only injectable and advise the woman to avoid sexual intercourse or use a barrier method of contraception (such as condoms) for 7 days.</li><li>For ulipristal acetate, give the injection 5 days after taking ulipristal acetate, and advise the woman to avoid sexual intercourse or use a barrier method of contraception (such as condoms) for 7 days.</li></ul></li><li>Advise the woman to take a pregnancy test no sooner than 3 weeks after the most recent episode of unprotected sexual intercourse (UPSI).</li></ul></li><li><strong>If the woman is changing from a combined hormonal contraceptive (CH</strong><strong>C</strong>):<ul><li>Give the progestogen-only injectable on day 1 of the hormone-free interval.<ul><li>No additional contraception is required.</li></ul></li><li>If the injection is given on week 1 of normal CHC use: <ul><li>Advise the woman to abstain from sex or use a barrier method of contraception (such as condoms) for 7 days. </li><li>If UPSI has occurred after day 3 of the hormone-free interval, advise the woman to restart the CHC method for at least 7 days.</li></ul></li><li>If the injection is given on weeks 2–3 of normal CHC use: <ul><li>No additional contraception is required if the CHC method has been used consistently and correctly for the previous 7 days.</li></ul></li></ul></li><li><strong>If the woman is changing from the progestogen-only pill (POP) or </strong><strong>levonorgestrel intrauterine system (LNG-IUS):</strong><ul><li>The progestogen-only injectable can be given at any time in the menstrual cycle.</li><li>Advise the woman to abstain from sex or use a barrier method of contraception (such as condoms) for 7 days, or continue the existing method for 7 days, regardless of when in the menstrual cycle the injection is given.</li></ul></li><li><strong>If the woman is changing from another injectable progestogen-only contraceptive:</strong><ul><li>Give the progestogen-only injectable on or before the day the next injection is due.<ul><li>No additional contraception is required.</li></ul></li></ul></li><li><strong>If the woman is changing from a progestogen-only implant:</strong><ul><li>Give the progestogen-only injectable up to 3 years after insertion of the implant.<ul><li>No additional contraception is required.</li></ul></li><li>If the injection is given more than 3 years after insertion of the implant: <ul><li>Advise the woman to abstain from sex or use a barrier method of contraception (such as condoms) for 7 days after the injection.</li><li>Consider the need for emergency contraception or a pregnancy test (no sooner than 3 weeks after the most recent UPSI) if pregnancy cannot be excluded. For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-emergency/index.html">Contraception - emergency</a>.</li></ul></li></ul></li><li><strong>If the woman is changing from a barrier method of contraception (such as condoms), or a copper </strong><strong>intrauterine device (Cu-IUD):</strong><ul><li>Give the progestogen-only injectable on day 1–5 of the menstrual cycle.<ul><li>No additional contraception is required.</li></ul></li><li>If the progestogen-only injectable is given at any other time in the menstrual cycle:<ul><li>Advise the woman to abstain from sex for 7 days, or continue the existing method for at least 7 days.</li></ul></li></ul></li></ul><!-- end field 6ebe6b3c-8bb7-4f01-8cdb-30b706a6f969 --><!-- end item 08c75333-5285-48ff-8192-f303c4aa83af --></div></section><section aria-labelledby="types-of-progestogen-only-injectable" class="ChapterBody-module--wrapper--2HCfk "><h4 id="types-of-progestogen-only-injectable">What types of progestogen-only injectables are available?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 428c7862-cae3-4c26-b957-694cc2eada54 --><!-- begin field ccc6cb79-7685-4676-9599-7de2c0b2a81a --><ul><li>Three progestogen-only injectables are currently available in the UK:</li><ul><li>Depot medroxyprogesterone acetate 150 mg (Depo-Provera®) is the most commonly used progestogen-only injectable and is licensed for long-term use.</li><ul><li>It is given every 12 weeks by deep intramuscular injection.</li></ul><li>Depot medroxyprogesterone acetate 104 mg (Sayana Press®) is also licensed for long-term use.</li><ul><li>It is given every 13 weeks by subcutaneous injection.</li><li>Women may self-administer Sayana Press® after the first injection once they have received training in injection technique and the administration schedule from a healthcare professional.</li></ul><li>Norethisterone enantate, 200 mg (Noristerat®) is rarely used and is only licensed for short-term use (two injections).</li><ul><li>It is given every 8 weeks apart by deep intramuscular injection.</li></ul></ul></ul><!-- end field ccc6cb79-7685-4676-9599-7de2c0b2a81a --><!-- end item 428c7862-cae3-4c26-b957-694cc2eada54 --></div></section><section aria-labelledby="mechanism-of-action" class="ChapterBody-module--wrapper--2HCfk "><h4 id="mechanism-of-action">How do progestogen-only injectables work?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 3869a665-936a-4e5b-9a6a-c8cdd6978a0d --><!-- begin field 247ebe23-1759-4892-8f5b-42bd8160350b --><ul><li>Progestogen-only injectables (depot medroxyprogesterone acetate and norethisterone enantate) prevent pregnancy by the inhibition of ovulation and thickening of the cervical mucus, thereby presenting a barrier for sperm penetration.</li><li>In addition, changes to the endometrium make it an unfavourable environment for implantation.<br></li></ul><!-- end field 247ebe23-1759-4892-8f5b-42bd8160350b --><!-- end item 3869a665-936a-4e5b-9a6a-c8cdd6978a0d --></div></section><section aria-labelledby="choice-of-progestogen-only-injectable" class="ChapterBody-module--wrapper--2HCfk "><h4 id="choice-of-progestogen-only-injectable">Which progestogen-only injectable should I recommend?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 9fba6195-a662-49f6-b7d7-a6ce00af5d6a --><!-- begin field db90c412-b3ca-4a82-b4d2-a6ce00af5f44 --><ul><li>If the woman requires contraception for only a few months (short-term use), consider either:<ul><li>Depot medroxyprogesterone acetate (Depo-Provera® or Sayana Press®), <em>or</em></li><li>Norethisterone enantate (Noristerat®).</li></ul></li><li>If the woman requires long-term contraception, consider:<ul><li>Depot medroxyprogesterone acetate (Depo-Provera® or Sayana Press®).<ul><li>Women may self-administer Sayana Press® after the first injection once they have received training in injection technique and the administration schedule from a healthcare professional.</li></ul></li></ul></li></ul><!-- end field db90c412-b3ca-4a82-b4d2-a6ce00af5f44 --><!-- end item 9fba6195-a662-49f6-b7d7-a6ce00af5d6a --></div></section><section aria-labelledby="when-to-start-amenorrhoea" class="ChapterBody-module--wrapper--2HCfk "><h4 id="when-to-start-amenorrhoea">Amenorrhoea, postpartum, termination of pregnancy, or miscarriage</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 4eb63584-fbfa-4146-ab34-a6ce00b1a412 --><!-- begin field 62c66409-ccb4-46b5-b0f4-a6ce00b1a663 --><ul><li><strong>If the woman is amenorrhoeic:</strong><ul><li>Give the progestogen-only injectable at any time if it is reasonably certain the woman is not pregnant. <ul><li>Advise the woman to abstain from sex or use a barrier method of contraception (such as condoms) for 7 days.</li></ul></li></ul></li><li><strong>If the woman is postpartum (whether breastfeeding or not):</strong><ul><li>Give the progestogen-only injectable before day 21 postpartum:<ul><li>No additional contraception is required.</li></ul></li><li>If the progestogen-only injectable is given on or after day 21 postpartum:<ul><li>Advise the woman to avoid sex or use a barrier method of contraception (such as condoms) for 7 days, unless menstruation has started and the injection has been given on days 1–5.</li></ul></li></ul></li><li><strong>If the woman has had a miscarriage or termination of pregnancy:</strong><ul><li>If gestation is less than 24 weeks, ideally give the progestogen-only injectable immediately after a miscarriage, surgical termination, or the first part of a medical termination.<ul><li>If the progestogen-only injectable is given within 5 days of miscarriage or termination, no additional contraception is required.</li><li>If the progestogen-only injectable is given more than 5 days after miscarriage or termination, advise the woman to abstain from sex or use a barrier method of contraception (such as condoms) for 7 days.</li></ul></li><li>If gestation is 24 weeks or more, treat as for a woman who is postpartum.</li></ul></li></ul><!-- end field 62c66409-ccb4-46b5-b0f4-a6ce00b1a663 --><!-- end item 4eb63584-fbfa-4146-ab34-a6ce00b1a412 --></div></section><section aria-labelledby="basis-for-recommendation-272" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-272">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 272525d0-0e4a-48e8-816d-a7a700e7d7dc --><!-- begin field 687a99cf-474a-40d5-a523-a7a700e7d993 --><h5>Types of progestogen-only injectable</h5><ul><li>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline, <em>Progestogen-only injectables</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2014b</a>] and the manufacturers' Summaries of Products Characteristics [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2015b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2016d</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2016e</a>].</li></ul><h5>Mechanism of action</h5><ul><li>This information is based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Progestogen-only injectables </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2014b</a>].</li></ul><h5>When to start</h5><ul><li>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines <em>Progestogen-only injectables</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2014b</a>], and <em>Contraception after pregnancy </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2017b</a>], the <em>UK Medical Eligibility Criteria</em> <em>for contraceptive use</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2016</a>], a statement from the FSRH clinical effectiveness unit [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2015b</a>], and the manufacturers' Summaries of Product Characteristics [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2015b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2016d</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2016e</a>].</li></ul><h5>Progestogen-only injectable use in breastfeeding women</h5><ul><li>The FSRH advises that the progestogen-only injectable can be given on day 21 postpartum [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2016</a>].</li><li>However the manufacturers advise that it is given no sooner than 6 weeks postpartum [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2015b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2016d</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2016e</a>].</li></ul><!-- end field 687a99cf-474a-40d5-a523-a7a700e7d993 --><!-- end item 272525d0-0e4a-48e8-816d-a7a700e7d7dc --></div></section></section><section aria-labelledby="information-advice" class="ChapterBody-module--wrapper--2HCfk "><h3 id="information-advice">What information and advice should I give a woman who is considering using a progestogen-only injectable?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 51bb649c-7cee-4594-b44f-b752f11514df --><!-- begin field b60a1996-2922-486d-8420-4bc58f43cf77 --><ul><li><strong>Discuss:</strong><ul><li>The <a class="topic-reference internal-reference" href="index.html#mechanism-of-action">mechanism of action</a> of the progestogen-only injectable.</li><li>The <a class="topic-reference internal-reference" href="index.html#advantages-disadvantages">advantages, disadvantages, and risks</a> of the progestogen-only injectable.</li><li>The <a class="topic-reference internal-reference" href="index.html#efficacy">efficacy</a> of the progestogen-only injectable.</li><li>What happens when the progestogen-only injectable is stopped.<ul><li>Advise the woman that there could be a delay of up to 1 year in the return of normal fertility. Menstruation can take several months to return to normal.</li></ul></li></ul></li><li><strong>Give advice on:</strong><ul><li>The possible <a class="topic-reference internal-reference" href="index.html#risks-adverse-effects">adverse effects</a> (such as <a class="topic-reference internal-reference" href="index.html#risks-adverse-effects">menstrual irregularities</a>) of the progestogen-only injectable. </li><li>How to manage a <a class="topic-reference internal-reference" href="index.html#late-repeat">late repeat</a> of the injection.</li><li>The link between <em>Human papilloma viru</em>s (HPV) and cervical cancer, as well as strategies to reduce that risk. For more information see the CKS topic on <a class="topic-reference external-reference" href="../../../cervical-cancer-hpv/index.html">Cervical cancer and HPV</a>.</li><li>The need for routine cervical cytology screening. </li><li>The possibility of <a class="topic-reference internal-reference" href="index.html#drug-interactions">drug interactions</a>.</li></ul></li><li><strong>Also provide written information on the progestogen-only injectable.</strong><ul><li>The Family Planning Association provides a useful leaflet with information for users of the <a href="http://www.fpa.org.uk/sites/default/files/contraceptive-injections-your-guide.pdf" data-hyperlink-id="e939164b-7e8f-44ba-a598-a93100b9e5dd">progestogen-only injectable</a>. </li></ul></li></ul><!-- end field b60a1996-2922-486d-8420-4bc58f43cf77 --><!-- end item 51bb649c-7cee-4594-b44f-b752f11514df --></div><section aria-labelledby="late-repeat" class="ChapterBody-module--wrapper--2HCfk "><h4 id="late-repeat">What should I do if the repeat injection is late?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ce9b66df-aaf5-4413-92a9-a7a700e873b4 --><!-- begin field 4fce2837-95a3-4006-b419-a7a700e875e8 --><ul><li><strong>If it has up to </strong><strong>14 weeks since the last injection</strong><strong> of depot medroxyprogesterone or 10 weeks for norethisterone enantate was given</strong>:<ul><li>Give the repeat injection.</li><li>No additional contraception is needed.</li></ul></li><li><strong>If it has been more than 14 weeks since the the last injection of depot medroxyprogesterone or 10 weeks for norethisterone enantate was given </strong><strong>and:</strong><ul><li>Unprotected sexual intercourse (UPSI) has occurred within the last 5 days:<ul><li>Offer emergency contraception. For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-emergency/index.html">Contraception - emergency</a>.</li><li>Bridging methods such as progestogen-only pills (POPs) or combined hormonal contraception (CHC) are preferred, but the repeat injection can be considered.</li><li>Advise the woman to avoid intercourse or use a barrier method of contraception (such as condoms) for the next 7 days, and to take a pregnancy test no sooner than 3 weeks after the last episode of UPSI. F</li></ul></li><li>UPSI has occurred more than 5 days ago <em>and</em> within the last 5 days: <ul><li>Offer oral emergency hormonal contraception.</li><li>Bridging methods such as POPs or CHC are preferred, but the repeat injection can be considered.</li><li>Advise the woman to avoid intercourse or use a barrier method of contraception (such as condoms) for the next 7 days, and to take a pregnancy test no sooner than 3 weeks after the last episode of UPSI. </li></ul></li><li>UPSI has occurred more than 5 days ago, but within the last 3 weeks:<ul><li>Do not offer emergency contraception.</li><li>Bridging methods such as POPs or CHC are preferred, but the repeat injection can be considered.</li><li>Advise the woman to avoid intercourse or use a barrier method of contraception (such as condoms) for the next 7 days, and to take a pregnancy test no sooner than 3 weeks after the last episode of UPSI. </li></ul></li><li>UPSI has occurred more than 3 weeks ago:<ul><li>Do not offer emergency contraception.</li><li>Perform a pregnancy test, and administer the progestogen-only injectable if this is negative.</li><li>Advise the woman to avoid intercourse or use a barrier method of contraception (such as condoms) for the next 7 days.</li></ul></li></ul></li><li><strong>If the timing of the previous depot medroxyprogesterone acetate injection is unknown</strong><ul><li>Repeat the injection, provided it is reasonably certain that the woman is not pregnant.</li><li>Advise the woman to avoid intercourse or use a barrier method of contraception (such as condoms) for 7 days after the injection.</li></ul></li></ul><!-- end field 4fce2837-95a3-4006-b419-a7a700e875e8 --><!-- end item ce9b66df-aaf5-4413-92a9-a7a700e873b4 --></div></section><section aria-labelledby="pregnancy" class="ChapterBody-module--wrapper--2HCfk "><h4 id="pregnancy">How should I manage a woman who becomes pregnant whilst using the progestogen-only injectable?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 91005fec-b157-498e-b9e8-337109081932 --><!-- begin field 7ffde608-11a1-4723-81f8-7d5899224c15 --><ul><li>If a woman is found to be pregnant whilst using the progestogen-only injectable, reassure her that there is no evidence of harm to the fetus or the mother.<br></li></ul><!-- end field 7ffde608-11a1-4723-81f8-7d5899224c15 --><!-- end item 91005fec-b157-498e-b9e8-337109081932 --></div></section><section aria-labelledby="basis-for-recommendation-159" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-159">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 15999f55-6f08-419c-af63-a7a700e910c3 --><!-- begin field 2b16ae3f-751b-4e56-ad5d-a7a700e91276 --><h5>Information and advice</h5><ul><li>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Progestogen-only injectables </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2014b</a>].</li></ul><h5>Human papilloma virus and depot medroxyprogesterone (DMPA) injectable</h5><ul><li>There is a weak association between cervical cancer and use of DMPA for 5 years or longer. Any increased risk appears to reduce with time after stopping and could be due to confounding factors [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2014b</a>].</li></ul><h5>Late repeat injection</h5><ul><li>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Progestogen-only injectables</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2014b</a>].</li></ul><h5>Pregnancy</h5><ul><li>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline <em>Progestogen-only injectables </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2014b</a>], the <em>UK Medical Eligibility Criteria</em> <em>for contraceptive use</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2016</a>], and the manufacturers' Summaries of Product Characteristics [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2015b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2016d</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2016e</a>].</li><li>The manufacturers of Depo-Provera® and Sayana Press® state that infants born from accidental pregnancies that occur 1–2 months after injection may be at increased risk of low birth weight and neonatal death. <ul><li>However, this was based on one observational study (n = 1207) in Thailand, with many confounding factors.</li><li>The FSRH advises that there is no harm to the fetus or to the mother [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2014b</a>].</li></ul></li></ul><!-- end field 2b16ae3f-751b-4e56-ad5d-a7a700e91276 --><!-- end item 15999f55-6f08-419c-af63-a7a700e910c3 --></div></section></section><section aria-labelledby="advantages-disadvantages" class="ChapterBody-module--wrapper--2HCfk "><h3 id="advantages-disadvantages">What are the advantages and disadvantages of progestogen-only injectables?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 2b5dc7d1-cade-4362-a83b-383728c0ba33 --><!-- begin field 2cefc7c3-b441-4ac7-ace6-bc72f2517fd6 --><p>This information relates primarily to depot medroxyprogesterone acetate (DMPA) and is assumed to apply to norethisterone enantate (NET-EN).</p><h4>Advantages</h4><ul><li>It is very <a class="topic-reference internal-reference" href="index.html#efficacy">effective</a>.</li><li>Users do not have to think about contraception for as long as the injection lasts — 12 weeks for DMPA and 8 weeks for NET-EN.</li><li>Sex need not be interrupted to use contraception.</li><li>It can be used when breastfeeding.</li><li>There are no known interactions with any medications (including liver enzyme-inducing drugs).</li><li>It may reduce heavy painful periods and help with premenstrual symptoms.</li><li>It can be used in situations where combined hormonal contraceptives are not recommended. </li><li>It can be used by women with a body mass index (BMI) greater than 35 kg/m2 (but may cause further weight gain).</li><li>It may reduce the risk of ovarian and endometrial cancer.</li></ul><h4>Disadvantages</h4><ul><li>It is not rapidly reversible. After stopping use of progestogen-only injectables:<ul><li>There could be a delay of up to 1 year in the return of normal fertility.</li><li>Menstruation can take several months to return to normal.</li></ul></li><li>It does not protect against sexually transmitted infections (STIs).</li><li><a class="topic-reference internal-reference" href="index.html#risks-adverse-effects">Adverse effects</a> including unscheduled bleeding and weight changes may occur. </li></ul><!-- end field 2cefc7c3-b441-4ac7-ace6-bc72f2517fd6 --><!-- end item 2b5dc7d1-cade-4362-a83b-383728c0ba33 --></div><section aria-labelledby="basis-for-recommendation-0b5" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-0b5">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 0b5535b5-e533-436f-b280-7e2d85d8aca2 --><!-- begin field c0827355-1f73-42e0-81f7-e2339b61ee0d --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guideline, <em>Progestogen-only injectables</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2014b</a>] and the National Institute for Heath and Care Excellence (NICE) guidance <em>Long-acting reversible contraception</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014</a>].</p><!-- end field c0827355-1f73-42e0-81f7-e2339b61ee0d --><!-- end item 0b5535b5-e533-436f-b280-7e2d85d8aca2 --></div></section></section><section aria-labelledby="risks-adverse-effects" class="ChapterBody-module--wrapper--2HCfk "><h3 id="risks-adverse-effects">What are the possible risks and adverse effects of progestogen-only injectables?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 6a213420-3457-4e42-86e3-d552a22f2a96 --><!-- begin field 07f9e2d7-18dd-48c9-b6a4-db95df2af373 --><ul><li><strong>Menstrual irregularities </strong>— for more information,<strong> </strong>see the section on <a class="topic-reference internal-reference" href="index.html#menstrual-irregularities">Unscheduled bleeding</a>.</li><li><strong>Weight gain </strong>— depot medroxyprogesterone acetate (DMPA) is associated with weight gain — up to 2–3 kg in weight over the first year of use.<ul><li>A higher initial body mass index (BMI) is predictive of weight gain in adolescents.</li><li>Women who experience a weight gain of more than 5% in the first 6 months are likely to experience continued weight gain.</li><li>If a woman using the progestogen-only injectable presents with a weight gain:<ul><li>Advise her that weight gain is common with DMPA use.</li><li>Exclude pregnancy.</li><li>Offer lifestyle advice (diet and exercise).</li></ul></li><li>If weight gain is severe, consider:<ul><li>Referring to a dietitian.</li><li>Investigating for other causes of severe weight gain (such as eating disorders, depression, or thyroid disease).</li></ul></li></ul></li><li><strong>Cancer risk</strong><ul><li>There is a possible increased risk of breast cancer. However, this risk is very small compared with the overall risk of developing breast cancer and gradually disappears within 10 years after stopping the progestogen-only injectable.<ul><li>For more information about the risks, which are the same as for progestogen-only pills, see the section on <a class="topic-reference internal-reference" href="../progestogen-only-pill/index.html#risks-adverse-effects">Adverse effects</a> in the <a class="topic-reference internal-reference" href="../progestogen-only-pill/index.html">Scenario: Progestogen-only pill</a>.</li></ul></li><li>There is a weak association between cervical cancer and use of DMPA for 5 years or longer. Any increased risk is reduced with time after stopping.<ul><li>Ensure women requesting DMPA are undergoing routine cervical screening.</li></ul></li></ul></li><li><strong>Effect on bone mineral density (BMD)</strong> — the use of DMPA is associated with a small loss of BMD with long-term use (more than 1 year). However, this is usually recovered after stopping the injection, and there is no evidence that DMPA increases the risk of fracture.<ul><li>If a woman wishes to use DMPA long-term, review the woman every 2 years to assess the risks and benefits of the injection and to decide whether treatment can be continued.</li><li>Consider other methods of contraception for:<ul><li>Women younger than 18 years of age (consider the DMPA injection only if all other methods of contraception are unsuitable or unacceptable).</li><li>Women with significant risk factors for osteoporosis (for example long-term corticosteroid use).<strong> </strong>For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../osteoporosis-prevention-of-fragility-fractures/index.html">Osteoporosis - prevention of fragility fractures</a>.</li></ul></li></ul></li><li><strong>Injection site reactions</strong><ul><li>These are more common with subcutaneous (Sayana Press®) than intramuscular DMPA (Depo Provera®), and includes pain, abscess, and scarring.</li></ul></li><li><strong>There is little evidence that the use of the progestogen-only injectable causes the following reported adverse effects:</strong><ul><li>Mood changes.</li><li>Loss of libido.</li><li>Acne.</li><li>Headache.</li><li>Hot flushes</li><li>Vaginitis.</li></ul></li></ul><!-- end field 07f9e2d7-18dd-48c9-b6a4-db95df2af373 --><!-- end item 6a213420-3457-4e42-86e3-d552a22f2a96 --></div><section aria-labelledby="basis-for-recommendation-5e6" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-5e6">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 5e680cbf-48b4-4dfa-827f-41ecbab441ef --><!-- begin field 4be32b49-6744-488d-a933-3a9028f1ee5b --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines, <em>Progestogen-only injectables </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2014b</a>] and <em>Problematic bleeding with hormonal contraception</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2015c</a>], and the National Institute for Heath and Care Excellence (NICE) guidance <em>Long-acting reversible contraception</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014</a>] and <em>Suspected cancer: recognition and referral</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2015</a>].</p><h5>Progestogen-only injectables and cervical cancer risk</h5><ul><li>A pooled analysis from two case-control studies suggested a possible increased risk of cervical cancer with use for 5 years or more (RR 1.2, 95% CI 1.0–1.6) [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2014b</a>].</li><li>A re-analysis of epidemiological data also found a small significant increased risk of invasive cervical cancer (RR 1.22, 95% CI 1.01–1.46) in women who had used depot medroxyprogesterone acetate (DMPA) for more than 5 (mean 8.8) years [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2014b</a>].</li></ul><!-- end field 4be32b49-6744-488d-a933-3a9028f1ee5b --><!-- end item 5e680cbf-48b4-4dfa-827f-41ecbab441ef --></div></section><section aria-labelledby="menstrual-irregularities" class="ChapterBody-module--wrapper--2HCfk "><h4 id="menstrual-irregularities">How should I manage unscheduled bleeding in women using the progestogen-only injectable?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item e1e0ff97-bd98-40f2-9ebd-a6ce00b8d593 --><!-- begin field 463d7fd8-e289-457b-a74d-a6ce00b8d773 --><ul><li> <strong>Exclude or manage situations which could result in unscheduled bleeding</strong>, such as:<ul><li>Sexually transmitted infections (STIs) — as a minimum, test for <em>Chlamydia trachomatis</em>. The risk of STIs is increased if the woman is under 25 years, has a new sexual partner, or has had more than one sexual partner in the last year. For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../chlamydia-uncomplicated-genital/index.html">Chlamydia - uncomplicated genital</a>.</li><li>Pregnancy — perform a pregnancy test.</li><li>Gynaecological conditions such as cervical cancer — if this is suspected, refer women the woman using a suspected cancer pathway referral (for an appointment within 2 weeks). For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../gynaecological-cancers-recognition-referral/index.html">Gynaecological cancers - recognition and referral</a>.</li><li>Endometrial cancer — refer women aged 55 and older using a suspected cancer pathway referral (for an appointment within 2 weeks) if they have menstrual irregularities. Refer women younger than 55 years if they have risk factors for endometrial cancer and persistent, problematic bleeding after the first 3 months of use, or if they present with a change in bleeding pattern after at least 3 months of use.<br>For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../gynaecological-cancers-recognition-referral/index.html">Gynaecological cancers - recognition and referral</a>.</li><li>Drug interactions.</li></ul></li><li><strong> Consider performing a pelvic and speculum examination:</strong><ul><li>For persistent bleeding beyond the first 3 months of use — unscheduled bleeding is common in the first 3 months of starting a new hormonal contraceptive method.</li><li>For new symptoms or a change in bleeding after at least 3 months of use.</li><li>If the woman has not participated in the National Cervical Screening programme regularly. For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../cervical-cancer-hpv/index.html">Cervical cancer and HPV</a>.</li><li>If requested by the woman.</li><li>If there are other symptoms such as pelvic pain, dyspareunia, or post coital bleeding. </li></ul></li><li>If no other underlying cause of irregular bleeding is suspected, and speculum and pelvic examination is normal, the bleeding can be assumed to be caused by the progestogen-only injectable.<ul><li>Reassure the woman that bleeding disturbances are common and that:<ul><li>Around 1 in 10 women may be amenorrhoeic in the first 3 months of use.</li><li>Rates of amenorrhoea increase with duration of use.</li><li>Around 50% or more of women are amenorrhoeic at 12 months.</li></ul></li><li>Continue with the injectable if the woman is happy to continue.</li></ul></li><li>However, if bleeding is problematic, consider treating with:<ul><li>A combined oral contraceptive (30–35 micrograms of ethinylestradiol with levonorgestrel or norethisterone) either cyclically or continuously for up to 3 months provided it is not contraindicated (off-label use). For more information, see the Scenario: Combined oral contraceptive pill in the CKS topic on Contraception - combined hormonal methods.</li><li>Mefenamic acid 500 mg two or three times a day (or tranexamic acid 1 g four times a day) for 5 days. For more information, see the section on <a class="topic-reference external-reference" href="../../../menorrhagia/prescribing-information/index.html">Prescribing information</a> in the CKS topic on <a class="topic-reference external-reference" href="../../../menorrhagia/index.html">Menorrhagia</a>.</li><li>Changing to another contraceptive method. For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-assessment/index.html">Contraception - assessment</a>.</li></ul></li><li>Be aware that: <ul><li>Some women experience prolonged amenorrhoea; this is most likely in older women and is usually acceptable to the woman.</li><li>Amenorrhea is more likely with depot medroxyprogesterone acetate (DMPA) than norethisterone enantate (NET-EN).</li><li>Irregular bleeding may continue for some months after stopping the injection.</li></ul></li><li>There is no evidence that reducing the injection interval for DMPA improves bleeding.</li></ul><!-- end field 463d7fd8-e289-457b-a74d-a6ce00b8d773 --><!-- end item e1e0ff97-bd98-40f2-9ebd-a6ce00b8d593 --></div></section></section><section aria-labelledby="drug-interactions" class="ChapterBody-module--wrapper--2HCfk "><h3 id="drug-interactions">What advice should I give regarding potential drug interactions with the progestogen-only injectable?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item f628033b-6b0e-4d1f-a79c-251361b8b049 --><!-- begin field 7429cd7e-4600-4fdb-9ec4-802bb13280a9 --><ul><li>The efficacy of the progestogen-only injectable is not reduced by liver enzyme-inducing drugs. </li><li>Ulipristal acetate has the potential to reduce the efficacy of hormonal contraception.</li><ul><li>Advise women to start the progestogen-only injectable 5 days after taking ulipristal acetate and to use a barrier method of contraception (such as condoms) during this time and for the next 7 days. For more information see the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-emergency/index.html">Contraception - emergency</a>.</li></ul></ul><!-- end field 7429cd7e-4600-4fdb-9ec4-802bb13280a9 --><!-- end item f628033b-6b0e-4d1f-a79c-251361b8b049 --></div><section aria-labelledby="basis-for-recommendation-095" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-095">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 095fb170-bdc7-4f83-89b8-0a65e6e11908 --><!-- begin field f8cc9110-03c9-4c6f-aa8a-49ef6577ab50 --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines <em>Progestogen-only injectables</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2014b</a>], and <em>Drug interactions with hormonal contraception</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2012</a>], and a statement from the FSRH clinical effectiveness unit [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2015b</a>].</p><!-- end field f8cc9110-03c9-4c6f-aa8a-49ef6577ab50 --><!-- end item 095fb170-bdc7-4f83-89b8-0a65e6e11908 --></div></section></section><section aria-labelledby="efficacy" class="ChapterBody-module--wrapper--2HCfk "><h3 id="efficacy">How effective are progestogen-only injectables at preventing pregnancy?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 97b60a31-e2ed-44e6-ae92-a01f94252cd9 --><!-- begin field 445aa41a-63d7-465c-8d34-87f8baaf5437 --><ul><li>For comparison of the efficacy of progestogen-only injectables with other methods of contraception, see the CKS topic on <a class="topic-reference external-reference" href="../../../contraception-assessment/index.html">Contraception - assessment</a>.<ul><li>When used perfectly (consistently and correctly), 0.2% of women will conceive within the first year of use due to method failure.</li><li>When used typically, 6% of women will conceive within the first year of use due to method failure or user failure.</li></ul></li></ul><!-- end field 445aa41a-63d7-465c-8d34-87f8baaf5437 --><!-- end item 97b60a31-e2ed-44e6-ae92-a01f94252cd9 --></div><section aria-labelledby="basis-for-recommendation-795" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-795">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 795cfd6e-eeaa-44ee-b323-2257c3d46ae4 --><!-- begin field 2de0e38e-7b5c-4627-9968-24c84220ba84 --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines <em>Progestogen-only injectables </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2014b</a>].</p><!-- end field 2de0e38e-7b5c-4627-9968-24c84220ba84 --><!-- end item 795cfd6e-eeaa-44ee-b323-2257c3d46ae4 --></div></section></section><section aria-labelledby="follow-up" class="ChapterBody-module--wrapper--2HCfk "><h3 id="follow-up">What follow up should I arrange for a woman using a progestogen-only injectable?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item a5177b5f-e952-4399-afc8-5bd9eee5bfd2 --><!-- begin field ef4a8166-8e73-469d-819f-6003c0124bde --><ul><li>At the follow up visit, when the woman attends for a repeat injection:<ul><li>Check her knowledge of what to do if she is <a class="topic-reference internal-reference" href="index.html#late-repeat">late for injections</a>.</li><li>Address any issues or <a class="topic-reference internal-reference" href="index.html#risks-adverse-effects">adverse effects</a> she might have, such as weight gain and irregular menstrual bleeding.</li><li>Advise the woman to return if she experiences signs of infection at the site of the injection (for example redness, swelling, pain, or rash). For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../cellulitis-acute/index.html">Cellulitis - acute</a>.</li></ul></li><li>Review the woman every 2 years to assess the risks and benefits of the injection and to decide whether treatment can be continued.</li></ul><!-- end field ef4a8166-8e73-469d-819f-6003c0124bde --><!-- end item a5177b5f-e952-4399-afc8-5bd9eee5bfd2 --></div><section aria-labelledby="duration-of-use" class="ChapterBody-module--wrapper--2HCfk "><h4 id="duration-of-use">How long can the progestogen-only injection be used for?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 7a609318-e754-4f7a-b340-a6ce00bb20c0 --><!-- begin field 912ff558-5350-4b84-8331-a6ce00bb2287 --><p><strong>Depot medroxyprogesterone acetate </strong>(Depo-Provera® or Sayana Press®)</p><ul><li>No maximum duration of use is suggested in the Summaries of Product Characteristics.</li><li>Review women using depot medroxyprogesterone acetate every 2 years to discuss the benefits and potential risks of continuing this method of contraception.</li><li>When the woman reaches 50 years of age, stop depot medroxyprogesterone acetate and switch to one of the following methods:<ul><li>A non-hormonal method of contraception (the copper intrauterine device or barrier methods).</li><li>An alternative hormonal method of contraception (the progestogen-only pill, the progestogen-only implant, or the levonorgestrel intrauterine system).</li></ul></li></ul><p><strong>Norethisterone enantate </strong>(Noristerat®)</p><ul><li>Norethisterone enantate is only licensed for up to two injections, given 8 weeks apart.</li></ul><!-- end field 912ff558-5350-4b84-8331-a6ce00bb2287 --><!-- end item 7a609318-e754-4f7a-b340-a6ce00bb20c0 --></div></section><section aria-labelledby="timing-of-repeat-injections" class="ChapterBody-module--wrapper--2HCfk "><h4 id="timing-of-repeat-injections">How often should I repeat the progestogen-only injection?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item cef178cd-4518-4da6-a313-a6ce00bb130f --><!-- begin field 02b42a7f-b99b-40d0-bf02-a6ce00bb14f7 --><ul><li><strong>For Depo-Provera® </strong>(depot medroxyprogesterone acetate):<ul><li>Repeat the injection every 12 weeks.</li><li>However, if this is not possible, repeat injections can also be given up to 2 weeks early (every 10 weeks) or up to 2 weeks late (every 14 weeks).</li></ul></li><li><strong>For Sayana Press®</strong> (depot medroxyprogesterone acetate):<ul><li>Repeat the injection every 13 weeks.</li><li>However, if this is not possible, repeat injections can also be given up to 1 week late (every 14 weeks).</li></ul></li><li><strong>For Noristerat</strong><strong>® </strong>(norethisterone enantate):<ul><li>Repeat the injection after 8 weeks. <ul><li>Be aware that norethisterone enantate is licensed for up to two injections only, 8 weeks apart.</li></ul></li><li>However, if this is not possible, a repeat injection can also be given up to 2 weeks early (6 weeks apart) or up to 2 weeks late (10 weeks apart).</li></ul></li></ul><!-- end field 02b42a7f-b99b-40d0-bf02-a6ce00bb14f7 --><!-- end item cef178cd-4518-4da6-a313-a6ce00bb130f --></div></section><section aria-labelledby="basis-for-recommendation-878" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-878">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 8787b40b-9fb3-40b9-94f7-96b0e287b2cf --><!-- begin field d307cb97-3893-455d-bf55-1f15ec823d83 --><p>These recommendations are based on the Faculty of Sexual and Reproductive Healthcare (FSRH) clinical guidelines <em>Progestogen-only injectables </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2014b</a>], <em>Contraception for women aged over 40 years</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">FSRH, 2010b</a>] and the manufacturers' Summaries of Product Characteristics [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2015b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2016d</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2016e</a>].</p><!-- end field d307cb97-3893-455d-bf55-1f15ec823d83 --><!-- end item 8787b40b-9fb3-40b9-94f7-96b0e287b2cf --></div></section></section></section></div></div></div><div class="BackToTop-module--wrapper--2Z0EU"><nav aria-labelledby="back-to-top-link" class="BackToTop-module--nav--1DPZ6"><a class="BackToTop-module--anchor--1Nia6" id="back-to-top-link" href="index.html#content-start"><div class="container"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="icon" aria-hidden="true" focusable="false"><path d="M478.152 338.576c0 10.091-3.525 18.661-10.576 25.712l-21.424 21.424c-7.243 7.243-15.909 10.864-26 10.864-10.283 0-18.853-3.621-25.712-10.864L255.576 247.136 116.712 385.712c-6.859 7.243-15.429 10.864-25.712 10.864s-18.853-3.621-25.712-10.864l-21.424-21.424C36.621 357.429 33 348.859 33 338.576c0-10.091 3.621-18.757 10.864-26l186-186c7.051-7.051 15.621-10.576 25.712-10.576 9.909 0 18.576 3.525 26 10.576l185.712 186c7.243 7.243 10.864 15.909 10.864 26z" fill="currentColor"></path></svg> Back to top</div></a></nav></div></main><footer class="Footer-module--footer--2QrGZ"><div class="Footer-module--container--1iuoB"><a href="https://www.nice.org.uk/" class="Footer-module--logo--3DGKv" aria-label="Go to NICE home page"></a><nav class="Services-module--wrapper--2qOoE" aria-label="Our services"><ul class="Services-module--list--3SZQu"><li><a href="https://pathways.nice.org.uk/" class="Services-module--link--2y_1q">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Services-module--link--2y_1q">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Services-module--link--2y_1q">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Services-module--link--2y_1q">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary">BNF<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Services-module--link--2y_1q"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Services-module--visuallyHidden--t9mfm">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">Clinical Knowledge Summaries</span></a></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Services-module--link--2y_1q">Journals and databases</a></li></ul></nav><nav class="Pages-module--wrapper--30REl"><ul class="Pages-module--list--vvSk4"><li><a href="https://www.nice.org.uk/about">About NICE</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/into-practice">Into practice</a></li><li><a href="https://www.nice.org.uk/get-involved">Get involved with NICE</a></li><li><a href="https://www.nice.org.uk/get-involved/jobs">Jobs</a></li><li><a href="https://www.nice.org.uk/news">News</a></li><li><a href="https://www.nice.org.uk/news/nice-newsletters-and-alerts">Newsletters and alerts</a></li><li><a href="https://www.nice.org.uk/get-involved/contact-us">Contact us</a></li><li><a href="https://www.nice.org.uk/leave-feedback">Leave feedback</a></li><li><a href="https://www.nice.org.uk/re-using-our-content">Reusing our content</a></li><li><a href="https://www.nice.org.uk/re-using-our-content/uk-open-content-licence">NICE UK Open Content Licence</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/nice-syndication-api">Syndicate our content</a></li></ul></nav><div class="Social-module--wrapper--2nKsd"><ul class="Social-module--list--E5R5J" aria-label="NICE on social media"><li><a href="https://en-gb.facebook.com/NationalInstituteforHealthandCareExcellence/">Facebook</a></li><li><a href="https://twitter.com/NICEcomms">Twitter</a></li><li><a href="https://www.youtube.com/user/NICEmedia">YouTube</a></li><li><a href="https://www.instagram.com/nicecomms/">Instagram</a></li><li><a href="https://www.linkedin.com/company/national-institute-for-health-and-clinical-excellence">LinkedIn</a></li></ul></div></div><div class="Legal-module--wrapper--3AYMO"><div class="Legal-module--container--3TTBh"><nav class="Legal-module--menu--1e1Iy" aria-label="Legal menu"><ul><li><a href="https://www.nice.org.uk/accessibility">Accessibility</a></li><li><a href="https://www.nice.org.uk/freedom-of-information">Freedom of information</a></li><li><a href="https://www.nice.org.uk/glossary">Glossary</a></li><li><a href="https://www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li><li><a href="https://www.nice.org.uk/privacy-notice">Privacy notice</a></li><li><a href="https://www.nice.org.uk/cookies">Cookies</a></li></ul></nav><p class="Legal-module--copyright--34nsI">©<!-- --> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> <!-- -->2021<!-- -->. All rights reserved. Subject to<!-- --> <a href="https://www.nice.org.uk/terms-and-conditions#notice-of-rights">Notice of rights</a>.</p></div></div></footer></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/topics/contraception-progestogen-only-methods/management/progestogen-only-injectables/";/*]]>*/</script><script id="gatsby-chunk-mapping">/*<![CDATA[*/window.___chunkMapping={"polyfill":["/polyfill-2cb897c2a056d28c9332.js"],"app":["/app-53a71c38b210970893c4.js"],"component---cache-caches-gatsby-plugin-offline-app-shell-js":["/component---cache-caches-gatsby-plugin-offline-app-shell-js-258fa972005c75a2a109.js"],"component---src-pages-404-tsx":["/component---src-pages-404-tsx.4b20f8dadfa146d0f95d.css","/component---src-pages-404-tsx-db046304e34e9a4e982b.js"],"component---src-pages-about-development-tsx":["/component---src-pages-about-development-tsx.4c5b5dd941fb0f6fd929.css","/component---src-pages-about-development-tsx-a805dcaba6372bd3fd34.js"],"component---src-pages-about-index-tsx":["/component---src-pages-about-index-tsx.a9a4b7f951b698486005.css","/component---src-pages-about-index-tsx-d5e998d3f688352286e1.js"],"component---src-pages-index-tsx":["/component---src-pages-index-tsx.49dafffcf9ae0c5f0d9f.css","/component---src-pages-index-tsx-6cc2ff789de11ec327f6.js"],"component---src-pages-search-tsx":["/component---src-pages-search-tsx.f915457cd8b05c27e895.css","/component---src-pages-search-tsx-a51f99760cb0d47808e2.js"],"component---src-pages-specialities-tsx":["/component---src-pages-specialities-tsx.fc62cf637c7ba1e609e7.css","/component---src-pages-specialities-tsx-90b8d3e5a5a3bff52a17.js"],"component---src-pages-topics-tsx":["/component---src-pages-topics-tsx.dfa0c1027e3cbeb11bdc.css","/component---src-pages-topics-tsx-960f75c13acbee11c017.js"],"component---src-pages-whats-new-tsx":["/component---src-pages-whats-new-tsx.7f7660f22ce5e07ac85a.css","/component---src-pages-whats-new-tsx-f78b713a66b42005fd9f.js"],"component---src-templates-chapter-level-1-chapter-level-1-tsx":["/component---src-templates-chapter-level-1-chapter-level-1-tsx.1a16ce552cccd7e50c41.css","/component---src-templates-chapter-level-1-chapter-level-1-tsx-0a03778bb80ba711929e.js"],"component---src-templates-chapter-level-2-chapter-level-2-tsx":["/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css","/component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"],"component---src-templates-speciality-speciality-tsx":["/component---src-templates-speciality-speciality-tsx.fc62cf637c7ba1e609e7.css","/component---src-templates-speciality-speciality-tsx-3357943d471e489a1b5f.js"],"component---src-templates-topic-topic-tsx":["/component---src-templates-topic-topic-tsx.afc04214919e241c3c2e.css","/component---src-templates-topic-topic-tsx-f17fe03d0b9a54a96aea.js"]};/*]]>*/</script><script src="../../../../polyfill-2cb897c2a056d28c9332.js" nomodule=""></script><script src="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js" async=""></script><script src="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js" async=""></script><script src="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js" async=""></script><script src="../../../../app-53a71c38b210970893c4.js" async=""></script><script src="../../../../framework-34da02e39e1f104d9937.js" async=""></script><script src="../../../../webpack-runtime-28c424ef71f39faedaf0.js" async=""></script></body></html>